

Reviewed Preprint

v1 • January 21, 2026

Not revised

✉ For correspondence:

g.galea@ucl.ac.uk

* Present address: Department of Biochemistry, University of Cambridge, Hopkins Building, Tennis Court Road, Cambridge CB2 1QW, UK

Competing interests: No competing interests declared

Funding: See [page 21](#)

Reviewing editor: Fadel Tissir, UCLouvain, Belgium

© 2026, Ampartzidis et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Patient-specific iPSC models of neural tube defects identify underlying deficiencies in neuroepithelial cell shape regulation and differentiation

Ioakeim Ampartzidis^{1,*}, Elliott M Thompson¹, Yashica Gupta¹, Andrea Krstevski¹, Nicola Elvassore^{2,3}, Eirini Maniou^{2,3}, Paolo de Coppi^{4,5,6,7,8}, Gabriel L Galea¹ ✉

¹Developmental Biology and Cancer, UCL GOS Institute of Child Health, London, United Kingdom • ²Department of Industrial Engineering, University of Padua, Padua, Italy • ³Veneto Institute of Molecular Medicine, Padua, Italy • ⁴Stem Cells and Regenerative Medicine, UCL GOS Institute of Child Health, London, United Kingdom • ⁵Department of Development and Regeneration, Woman and Child and UZ Leuven Clinical Department of Obstetrics and Gynaecology, KU Leuven, Leuven, Belgium • ⁶Specialist Neonatal and Paediatric Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom • ⁷Medical and Surgical Department of the Fetus, Newborn and Infant, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy • ⁸NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom

eLife Assessment

The authors used genetic mutations in *VANGL2* to study cell morphological changes during differentiation of hPSCs and understand the mechanisms underlying neural tube closure defects. The findings are **important** as they establish a quantitative, reproducible 2D human iPSC-to-neural-progenitor platform for analyzing cell-shape dynamics during differentiation. The **convincing** evidence provided, combined with the relative simplicity of the model and its tractability as a patient-specific and reverse genetic platform, make it attractive.

[Editors' note: this paper was reviewed by *Review Commons* [✉](#).]

<https://doi.org/10.7554/eLife.110388.1.sa4>

Abstract

Spina bifida and anencephaly are neural tube defects caused by failure of embryonic neural tube closure. Successful closure requires apicobasal elongation and apical constriction of neuroepithelial cells. These critical behaviours have not been studied in human, patient-specific models. We characterise a human iPSC-derived neuroepithelial morphogenesis model that is highly reproducible across three parental iPSC lines of diverse origin and reprogramming technologies. Differentiated neuroepithelial cells actively undergo ROCK-dependent apical constriction. ROCK acts downstream of planar cell polarity/*VANGL2* in other species. We find that *VANGL2* is up-regulated and phosphorylated during iPSCs-to-neuroepithelial differentiation. The patient-identified *VANGL2-R353C* mutation does not alter *VANGL2* expression, localisation or phosphorylation, but reduces myosin-II phosphorylation and apical constriction relative to congenic control iPSCs. Non-congenic comparisons and forward genetic testing are also informative in this reproducible model. We compare lines reprogrammed from amniocytes of two patients with spina bifida, versus two controls. One patient-derived line forms a morphologically normal neuroepithelium, but fails to differentiate into neurons. The second fails to undergo apicobasal elongation, and harbours compound heterozygous mutations in the *MED24* gene previously implicated in neuroepithelial elongation in mice. Thus, iPSC-derived neuroepithelial modelling reveals mechanistic insights into conserved cell behaviours, including apical

constriction, apicobasal elongation and neural differentiation, links genetically-impaired apical constriction to human disease, and establishes patient-specific models which recapitulate failures across these heterogeneous neuroepithelial functions.

Introduction

Neural tube defects (NTDs), such as spina bifida and anencephaly, affect approximately 1:1,000 births globally¹. These severe neurodevelopmental malformations are caused by abnormal morphogenesis of the neural tube during embryonic development. The most severe NTDs result from failure of the physical process of neural tube closure, which in humans is completed by approximately 30 days gestation^{2,3}. Its completion during largely inaccessible stages of pregnancy has limited our ability to study neural tube closure in humans. This challenge is compounded by the multigenic causation of NTDs, as well as interactions of both maternal and embryonic genetics with environmental factors^{4–6}. Consequently, few patients receive an interpretable genetic diagnosis.

A few patient-identified mutations have been functionally validated in transgenic animal models^{5,7–9}. Mice and other vertebrates have been invaluable models for understanding the process of neural tube closure. Both mice and humans close their open neural tube regions – called neuropores – through progressive elevation of neural folds which meet at the dorsal midline and zipper along the body axis^{2,10}. Progression of closure requires the action of different cell types, particularly the surface ectoderm (future epidermis) and neuroepithelium (future brain and spinal cord)³. These cells coordinate multiple behaviours within and between each other. Neuroepithelial cells thicken along their apicobasal axis as they differentiate into a pseudostratified epithelium which undergoes interkinetic nuclear migration synchronised with cell cycle progression, superimposed on active apical constriction^{11–17}.

Neuroepithelial apical constriction is an evolutionarily conserved force-generating mechanism which contributes to neural tube closure in chordates including amphibians, birds and mammals³. It requires targeted localisation and phosphorylation of non-muscle myosin II in the cell's apical domain. Myosin binds filamentous (F-)actin, cross-linking filaments and generating contractile mechanical force that pulls actin filaments together through power strokes¹⁸. Neuroepithelial apical enrichment of F-actin and phosphorylation of myosin both require Rho-associated kinase (ROCK)¹⁹, which is in turn apically enriched at mediolateral cell borders at least in part by signalling through the non-canonical wingless homology (Wnt)/planar cell polarity (PCP) pathway^{20–22}. PCP components promote mediolaterally oriented neuroepithelial apical constriction in *Xenopus* frogs^{23,24}, chickens²² and mice^{15,20}, but this pathway has been difficult to study in human epithelial models due to lack of quantifiable readouts relevant to its functions *in vivo*.

PCP was originally described in *Drosophila* as a regulator of polarised cell features such as hair cell bristle orientation^{25–27}. Pathway components were later shown to be conserved in vertebrates and contribute to neural tube closure^{28–31}. The core PCP pathway involves signalling through asymmetric receptor complexes on adjacent cells, pairing van Gogh-like (VANGL) and Cadherin EGF LAG seven-pass G-type receptor (CELSR) proteins on one cell, with frizzled (FZD)/CELSR complexes on the adjacent cell³². Both VANGL and FZD branches of this pathway are involved in neural tube closure^{33,34}. VANGL2 can be activated through phosphorylation following binding of PCP Wnt ligands^{35,36}.

PCP signalling drives two functionally distinct processes in neuroepithelial cells essential for mammalian NT closure: early convergent extension and later apical constriction. Global genetic deletion of *Vangl2* precludes medial convergence and rostro-caudal elongation necessary to initiate neural tube closure in mouse embryos³⁷, although this effect may be partly mediated by the adjacent mesoderm³⁸. At later developmental stages, however, VANGL2 promotes cytoskeletal reorganisation involving F-actin planar polarisation and phosphorylation of non-muscle myosin IIB, likely by ROCK^{20,39–41}. However, we previously reported that VANGL2 is not cell-autonomously required for apical constriction of mouse neuroepithelial cells²⁰.

Mutations in PCP genes including *VANGL2*^{42–47} have been identified in patients who have NTDs and damaging variants in actomyosin-related cytoskeletal regulation are enriched in individuals with spina bifida⁴⁸. However, it has been challenging to study the regulation of apical constriction in human neuroepithelial cell models. A previous study described elegant modelling of neural tube closure by differentiation of induced pluripotent stem cells (iPSCs) on micropatterned surfaces⁴⁹. That model's formation of neuroepithelium enveloped within a larger cyst limits access to its apical surface for functional measurements, such as inference of mechanical tension through laser ablation assays. Similarly, previous studies have demonstrated that disruption of actomyosin regulation dilates apical surfaces on the inside of human iPSC-derived neuroepithelial spheres^{50,51}. Several models have also been described which enable studies into later stages of neuroepithelial function as they differentiate into neural progenitors and then neurons^{52–55}. While these neurogenesis models provide insights into later differentiation, they do not capture cell behaviours crucial for neural tube closure.

We recently characterised a minimal model of neuroepithelial morphogenesis in which a monolayer of cuboidal iPSCs apicobasally elongate into a complex, pseudostratified neuroepithelium with a planar morphology¹⁷. Importantly, this model presents readily accessible neuroepithelial apical surfaces which are directly comparable in size with those of mouse embryos¹⁷. Moreover, the same protocol can be extended to differentiate neuroepithelial cells into cortical neurons⁵⁶. This enables sequential assessment of neuroepithelial functions relevant to generating mechanical deformations which close the neural tube and their subsequent differentiation which normally occurs after completion of closure. Here, we show that neuroepithelial development in this model is reproducible, even when comparing non-congenic iPSC lines. We validate use of the model to study PCP components including ROCK and *VANGL2*, finding that a *VANGL2* point mutation previously identified in a patient⁴⁶ diminishes neuroepithelial apical constriction. Extension of the model to two iPSC lines derived from individuals who have spina bifida identifies line-specific deficiencies, including apicobasal elongation and neural cell differentiation, potentially relevant to their malformation. Strikingly, all three NTD-relevant lines – *VANGL2* point mutation and two patient-derived lines – present failures of distinct neuroepithelial functions, recapitulating the heterogeneity of these conditions.

Results

Lineage-specific marker expression precedes morphological changes during iPSC to neuroepithelium differentiation

Intra-line variability often limits the use of iPSCs to model multigenic diseases, such as NTDs, in which congenic controls are often impractical. In contrast, neuroepithelial differentiation through dual SMAD inhibition (Figure 1a [↗](#))^{17,56} is highly reproducible between different iPSC lines. We illustrate this by using three previously reported iPSC lines from healthy individuals, selected to represent different origins and reprogramming methods (Figure 1b [↗](#)). For each of the three iPSC lines, we analysed three independently differentiated plates, each representing a separate biological replicate. Line H0193b was reprogrammed from male (46XY) amniocytes through microfluidic delivery of modified mRNA^{57,58}. SFC086-03-01 was reprogrammed from adult female (46XX) fibroblasts using non-integrating Sendai virus^{17,59}. 802-30F was from endothelial cells of a Hispanic female (46XX) reprogrammed through StemRNA⁶⁰. Despite their varied origins, all three undergo equivalent, temporally predictable changes in epithelial morphology during neuroepithelial differentiation (Figure 1a–h [↗](#)).

These cells begin their differentiation as an apicobasally polarised cuboidal monolayer approximately 25 μm thick with large apical areas approximately 60 μm^2 ('day 2', Figure 1c–g [↗](#)). During differentiation, they double their apicobasal length into a pseudostratified epithelium¹⁷ approximately 55 μm thick, with small apical surfaces around 10 μm^2 ('day 8', Figure 1c–g [↗](#), Supplementary Figure 1a–c [↗](#)). Apicobasal elongation increases total epithelial volume,




Figure 1. Reproducible morphological and molecular evolution of iPSC differentiation into neuroepithelial cells.

iPSC1 is H0193b, iPSC2 is SFC086-03-01 and iPSC3 is 802-30F. **a**, Schematic representation of the neuroepithelial induction protocol. Sub-confluent human iPSCs (in grey) are passaged and seeded at full confluency from the start of differentiation and cultured for eight days, until reaching neuroepithelial maturity. Further passage at this stage forms neural rosettes and allows further differentiation into post-mitotic neurons⁵⁶. **b**, Summary of control lines used to validate reproducibility of differentiation into neuroepithelial cells. **c,d**, Representative high-resolution confocal top-view (**c**) and cross-section (**d**) images of day 2-8 cultures fluorescently labelled to show F-actin with inverted gray LUT. P values from one-way ANOVA with post-hoc Bonferroni. **e**, Dot plot representing cell's apical area across timepoints of neuroepithelial differentiation, in three iPSC lines. Black bars represent the median apical area across three independent culture plates of each line. **f**, Heatmaps of hiPSC2 representing the apical area size changes during differentiation, in a contiguous area of 1,200 μm^2 per timepoint. **g**, Quantification of epithelial thickness across neuroepithelial differentiation of control cell lines. Three culture replicates were measured for each time point and cell line. **h**, Dot plot representing the cell volume decrease across timepoints of differentiation with representative 3D volumetric images at day 2 and day 8 (**h'**). **i**, Representative western blot panel of NANOG, OCT4, CDH1, CDH2, PAX6, and LMNB protein levels across timepoints of neuroepithelial differentiation, in the iPSC2 line. **j,k**, Dot plots representing normalised band intensity of NANOG (**j**), and PAX6 (**k**), across differentiation for three control cell lines. NANOG expression is normalised to day 2 per line, whereas PAX6 is normalised to day 8 as it is not detected at day 2. P values from one-way ANOVA (**e,g**) or Wilcoxon paired test (**j,k**) with Bonferroni correction (***: $p \leq 0.001$, *: $p \leq 0.005$). Scale bar = 10 μm .

accommodating ongoing cell division¹⁷, yet the volume of individual cells decreases from 1,550 μm^3 at the start of differentiation to 500 μm^3 at the end (Figure 1h). This reduction in total cell volume is partly due to a halving of nuclear volume (Supplementary Figure 1d-e).

Neuroepithelial apical size and apicobasal thickness – properties whose dynamic control enables neural tube closure *in vivo*^{20,22,61,62} – are indistinguishable between non-congenic iPSC lines at each stage of differentiation analysed (Figure 1c-g). Equivalent neuroepithelial thickness and apical areas are also obtained in cultures differentiated by different investigators (Supplementary Figure 2). All lines show a non-linear morphological evolution during differentiation: apical area and apicobasal thickness remain similar between days 2 and 4 of differentiation, but then change rapidly from day 5 (Supplementary Figure 1a-c) until the end of differentiation on day 8 (Figure 1e-g). In contrast, their expression of pluripotency markers such as NANOG and OCT4 are rapidly lost between days 2 and 4 of differentiation (Figure 1i,j). The cadherin CDH1 is similarly down-regulated early during differentiation, switching to expression of the neuroepithelial CDH2 from day 4 of differentiation (Figure 1i), before morphological changes. The neuroepithelial marker PAX6 is detectably expressed from day 4 and its expression increases between day 4 and 8 (Figure 1i,k).

iPSC-derived neuroepithelial cells actively generate mechanical tension through apical constriction

While reproducible between cultures, apical areas are variable within individual cultures (Figure 1e): a hallmark of asynchronous apical constriction *in vivo*⁶³. Through live imaging, we observe that iPSC-derived neuroepithelial cells spontaneously and dynamically alter their apical area (Figure 2a). Pharmacological inhibition of the myosin-activating kinase ROCK increases neuroepithelial apical area (Figure 2b-c), as previously observed in mouse embryos with equivalent ROCK inhibition *in vivo*¹¹.

Acutely expanding apical cell areas produced corrugation of the apical domain in ROCK-inhibited cultures (Supplementary Figure 3a-b), suggestive of buckling due to expansion within fixed boundaries imposed by the culture dish.

The functional outcome of apical constriction is generation of mechanical tension which is transmitted between adjacent cells and pulls on the surrounding tissue^{20,64}.

Contractile neuroepithelial apical tension can be inferred through annular laser ablation assays^{11,20}, in which release of a small cluster of cells from their neighbours causes rapid retraction of the cell borders within the ablated ring (Figure 2d). The ablated surface remained within the focal plane after ablation, indicating minimal movement along the apical-basal axis. Their tension is significantly diminished following a short period of ROCK inhibition (Figure 2e), confirming that it is actively established through apical constriction.

In vivo, the Rho/ROCK/myosin pathway can be activated by PCP/VANGL2 signalling^{20,22}, and is well-established to promote apical constriction^{20,23,65}. We observe that VANGL2 and its binding partner scribbled (SCRIB) are expressed at low levels from early stages of neuroepithelial differentiation and are significantly up-regulated by the end of the differentiation period (Figure 2f,g). Both are co-localised on the cell's apical cortex (Supplementary Figure 4). Serine-79/82/84 tri-phosphorylation of VANGL2 also increases significantly during differentiation, with a particularly large up-regulation between days 4 and 6 (Figure 2h), coinciding with the reduction in apical area (Figure 1e). Thus, iPSC-derived neuroepithelial cells express the cellular machinery required for physiological control of apical constriction and actively establish apical tension *in vitro*.




Figure 2. iPSC-derived neuroepithelial cells undergo ROCK-dependent apical constrictions and up-regulate expression of the PCP co-receptor VANGL2.

a, Live imaging of day 8 neuroepithelial cultures stained with CellMask Actin dye. Arrows indicate the apical surface of a constricting cell (not its neighbours do not constrict). **b**, Representative F-actin-stained images of cultures treated vehicle or 10 μ M ROCK inhibitor (Y27632) for 4 hr. **c**, Dot plot representing the median apical area of day 8 SFC086 neuroepithelial cultures. **d**, Live-imaged membrane-stained day 8 neuroepithelial cultures before and after a circular laser ablation, shown by red dashed lines. Red ring indicates neuroepithelial deformation before and after the ablation, respectively. **e**, Median apical cluster constriction of neuroepithelial cells, across three independent replicates in one cell line. Each point represents the median displacement quantified in each plate after at least three laser ablations. **f,g**, Representative confocal images of SCRIB and VANGL2 immunolabelled cultures at day 2 and day 8, in top-view (**f**) and cross-section (**g**). Dashed lines indicate the basal side. **h**, Representative western blot panel of VANGL2, phosphorylated VANGL2 (pVANGL2), and GAPDH protein levels across timepoints of neuroepithelial differentiation. All analyses shown are in iPSC2. P values from Wilcoxon paired test with Bonferroni correction (**: $p \leq 0.01$, *: $p \leq 0.005$). Scale bars = 10 μ m.

An NTD-associated *VANGL2* mutation impairs neuroepithelial apical constriction

To our knowledge, no genetic mutations identified in human patients have previously been functionally associated with failure of apical constriction. The *VANGL2-R353C* mutation (Figure 3a) was initially reported in a fetus which had both anencephaly and spina bifida⁴⁶, and impairs other functions of PCP signalling in fruit flies⁶⁶. This point mutation causes a basic to polar amino acid switch in a C-terminal region (Supplementary Figure 5) which is highly conserved across species and mediates interactions with pathway adaptor proteins^{46,66}. We therefore considered it a high priority target for testing in a human system.

We find that *VANGL2-R353C* mutation does not alter overall *VANGL2* protein levels, phosphorylation (Figure 3b,c), or apical localisation (Supplementary Figure 6) in two iPSC clonal knock-in lines homozygous for this mutation compared with a congenic control line. Knock-in and congenic control lines retain their ability to differentiate into different germ layers (Supplementary Figure 7), achieve equivalent changes in neuroepithelial apicobasal thickness (Supplementary Figure 8a-c) and nuclear pseudostratification (Supplementary Figure 8d,e) during differentiation. The *VANGL2-R353C* mutation does not significantly alter cell volume, nor does it diminish extension of sub-apical protrusions which are characteristic of neuroepithelial cells⁶⁷ (Supplementary Figure 9).

VANGL2-R353C knock-in lines have significantly larger apical areas (Figure 3d,e) and less apical localisation of phosphorylated myosin regulatory light chain (Figure 3f,g) than their congenic controls. Laser ablation assays confirm that apical tension is significantly lower in *VANGL2-R353C* knock-in lines than their congenic controls (Figure 3h,i). Thus, this *VANGL2* mutation associated with human NTDs selectively impairs neuroepithelial apical constriction. This is consistent with previous reports in *Xenopus* that *Vangl2* knockdown diminishes apical constriction, but we had previously observed that mouse *Vangl2* knockout cells remain able to apically constrict when surrounded by cells which express this gene. We therefore tested whether global loss of *Vangl2* impairs neuroepithelial apical constriction in a mammalian model. As expected, mouse embryos globally lacking *Vangl2* fail to close their entire spinal neural tube, developing craniorachischisis (Supplementary Figure 10a). *Vangl2*-null neuroepithelial cells show an equivalent shift towards larger apical areas in embryos (Supplementary Figure 10b-d) as seen *in vitro* (Figure 3e). Neuroepithelial apical areas are $39 \pm 8\%$ (mean $\pm$ 95% CI) larger in *Vangl2* knockout embryos versus wild-type littermates (Supplementary Figure 10d). *VANGL2-R353C* knock-in iPSC-derived neuroepithelial apical areas were $98 \pm 32\%$ (mean $\pm$ 95% CI across both knock-in clones with three independent experiments each) larger than their wild-type counterpart. This suggests the *VANGL2-R353C* mutation can explain all the impairment of neuroepithelial apical constriction caused by loss of *Vangl2* action.

Establishment of patient-derived models of neuroepithelial dysfunction

As well as mechanistic and reverse genetic studies, an additional application of this highly reproducible model is patient-specific testing of key neuroepithelial behaviours (Figure 4a). Importantly, short-loop reprogramming of amniotic fluid stem cells with microfluidic delivery of modified mRNA⁵⁷ enables rapid generation of patient-specific models in the ~4 months between spina bifida diagnosis and birth (Figure 4a). As proof of principle, we used short-loop reprogramming to compare two iPSC lines derived from amniotic fluid cells of individuals who do not have spina bifida (here called GOC1-2 for simplicity) with two lines of individuals treated at Great Ormond Street Hospital who underwent foetal surgery for spina bifida (GOSB1-2). All four lines express comparably high levels of the iPSC marker NANOG before differentiation, and differentiate to form endoderm, ectoderm and mesoderm (Supplementary Figure 7).




Figure 3. VANG2-R353C mutation selectively impairs neuroepithelial apical constriction.

a, Schematic representation of PCP pathway, starting from non-canonical Wnt ligands (e.g. Wnt5a/11) interacting with membrane co-receptors and activating cytoskeletal remodeling responses. The transmembrane protein VANG2 interacts with CELSR, which results in downstream interaction with cytoplasmic proteins such as PRICKLE and SCRIB. The VANG2-R353C mutation is localised at the C-terminal region of the protein, in the prickles binding domain (Pk-D). **b**, Representative western blot against VANG2 and pVANG2 on day 8 of neuroepithelial differentiation in the isogenic control cell line (WT) and two knock in clones with the R353C mutation (KI-1 and KI-2). **c**, Dot plots representing VANG2 and pVANG2 relative band intensity levels after normalisation to GAPDH, respectively, across three replicates. Intensity levels across the three lines were normalised to the WT levels of each replicate. **d**, Representative high resolution confocal images of ZO-1 immunolabelled neuroepithelial cultures on day 8, across the WT and KI cell lines. **e**, Frequency plot showing the distribution of apical area sizes of three independent day 8 neuroepithelial cultures, across the WT and both knock-in (KIs) lines. *** $p < 0.001$ by Kolmogorov Smirnov test, lines are the aggregate of three independent differentiations per line. **f**, Representative confocal images of neuroepithelial cultures immunolabelled for phospho-myosin light chain (pMLC)II, comparing the WT and KI-1 and KI-2 cell lines. Top view shows the distribution of protein of interest across the apical areas and cross-section illustrates localisation along the apicobasal axis. Scale bar = 10 μm . **g**, Dot plot showing normalised paired relative apical pMLCII intensity, across the WT and KI-1 and KI-2 cell lines, on day 8 of differentiation. Relative apical intensity was normalised to WT and set at 1, for each paired analysis, across four independent plates. **h**, Live-imaged membrane-stained neuroepithelial sheet before and after a circular laser ablation, with overlaid image of post-ablation timepoint and particle image velocimetry (PIV) analysis. The size and colour of arrows in PIV analysis represent the direction and magnitude of recoil. Scale = 20 μm . **i**, Median apical cluster constriction of neuroepithelial cells, across seven independent replicates. Each point represents three individual quantifications in each plate and connected lines indicate paired cultures. P values from Wilcoxon paired test with Bonferroni correction (***: $p \leq 0.001$, *: $p \leq 0.005$, n.s.: not significant).




Figure 4. Spina bifida patient amniocyte-derived iPSC lines can identify line-specific deficiencies in neuroepithelial cell function.

a, Experimental timeline of patient amniocyte-derived iPSC lines, following microfluidic reprogramming. Whole exome sequencing (WES) was performed before and after reprogramming to identify line-specific deficiencies at genomic level and pair them to neuroepithelial and/or neural function level. Initial iPSC cell expansion is not shown, but adds a few weeks to the timelines, still within the remaining period of normal gestation. **b**, Representative high-resolution top-view and cross-section images of day 8 neuroepithelial cultures visualizing F-actin. Two control cell lines (GOC1 and GOC2) were compared with two SB patient-derived hiPSCs cell lines (GOSB1 and GOSB2). **c**, Dot plot representing cell apical areas across the GOC1, GOC2, GOSB1, and GOSB2 cell lines at day 8 of neuroepithelial differentiation. Three independent plates were quantified for each line and the median apical area for each plate is shown with a black bar. **d**, Quantification of epithelial thickness on day 2 and day 8 samples, across four cell lines, GOC1, GOC2, GOSB1, and GOSB2. Points represent independent plate quantification for each line. Three paired replicates were measured for each time point and each cell line. Statistical test used for median values across quantifications was Wilcoxon paired test values with post-hoc Bonferroni. **e**, Representative confocal images of LMN A/C, CDH2, SOX2, and LMNB immunolabelling in GOC2, and GOSB2, on day 8 of neuroepithelial differentiation. **f**, Venn diagrams of GOSB1 and GOSB2 (**f'**) gene lists, after exome-sequencing, with at least one genetic variation observed in other datasets. Other datasets include previously associated mutations identified in humans under after search for the term "Neural Tube Defect" and "Spina Bifida" in ClinVar dataset, Lee and Geeson⁵. **g**, Filtering of variants in GOSB1 and GOSB2 to identify NTD-associated variants predicted to have a high impact on the transcript and which have a frequency <0.1 in gnomAD exome datasets. **h**, RNA structure of the MED24 major allele and rare variant (gnomAD reference 17-40019203-C-CACAT, allele exome frequency 0.018) predicted by RNAFold⁶⁹. **i**, Bar plots representing normalised band intensity of MED24 across four cell lines. GOC2's intensity levels were set as 1 in each of three replicates. **j**, Western blot panel of iPSCs from four cell lines, GOC1, GOC2, GOSB2, and SFC086-06 showing MED24 protein and housekeeping GAPDH levels. Statistical test used for values was one-way ANOVA with post-hoc Bonferroni (***: $p \leq 0.001$, **: $p \leq 0.01$). Scale = 20 μ m.

Both control lines and the first spina bifida line - GOSB1 - achieve indistinguishable apical areas and thicknesses (Figure 4b-d), further testament to the excellent reproducibility of this modelling system when comparing non-congenic lines. In contrast, the spina bifida line GOSB2 fails to apicobasally elongate as much as other lines and retains larger apical areas (Figure 4b-d). We consider this is unlikely to represent an apical constriction defect: laser ablation assays show comparable retraction in the GOSB2 line compared with the other lines tested (Supplementary Figure 11). The epithelia GOSB2 cells form include mitotic cells which are not apically-located, in contrast to all other cells studied which are pseudostratified and localise their mitoses apically (Supplementary Figure 12). Unlike all other lines tested, differentiated GOSB2 cultures also show abnormally heterogenous expression of CDH2 while partially retaining lamin A/C (Figure 4e) at the end of the standard differentiation protocol.

Attempts to adapt the protocol to 'rescue' this phenotype are beyond the scope of this study given the excellent reproducibility of differentiation in the seven other lines presented here.

We performed whole exome sequencing of all four amniocyte-derived lines to identify coding variants of potential clinical relevance in GOSB1 and GOSB2. Variants were compared with a list of genes previously associated with NTDs in mice and/or humans (Figure 4f, Supplementary Table 1).

GOSB1 harbours 851 variant loci within 747 genes (Supplementary Table 2; Figure 4g). Of all genes with variants, 27 are NTD-associated, such as *ZEB2* (variant 2-144389425-T-C) and *ZIC5* (13-99970996-G-T). None of the variants in NTD-associated genes are predicted to have a high transcript impact and all are heterozygous.

GOSB2, which has a more severe neuroepithelial phenotype, has 1122 variant loci in 939 unique genes of which 43 are in NTD-associated genes (Supplementary Table 3; Figure 4g). In this line, six NTD-associated genes harbour variants predicted to have a high impact on transcript sequence: *CSNK2A1*, *FAM20C*, *LFNG*, *MED24* and *PCSK5*.

Of these, *CSNK2A1* (20-503643-G-GCATATTT), *MED24* (17-40019203-C-CACAT) and *PCSK5* (9-76175222-AAATGGAATGGAATGAAATGG-A) have gnomAD variant allele frequencies <0.1. *MED24* (formerly called *TRAP100*) is of particular interest because its deletion in mice results in a thin neuroepithelium which is not pseudostratified⁶⁸, equivalent to our observations during GOSB2 differentiation. This gene is part of the mediator complex involved in RNA polymerase II transcriptional co-activation. GOSB2 cells have compound heterozygous frameshift mutations in the same repetitive region of the final exon of this gene. We additionally confirmed that the same *MED24* variants are present in independent exome sequencing of amniocytes from which GOSB2 had been derived (not shown). Both frameshifts are in the 3' untranslated region but are predicted to alter RNA structure, causing loss of a multi-branch loop (Figure 4h), and may therefore diminish binding of translation-regulating proteins. To test this, we compared *MED24* protein levels between GOSB2 iPSCs and three control lines, finding reduced protein abundance compared to all three controls (Figure 4i,j). Although genetic rescue experiments are beyond the scope of this study, particularly given the likelihood of gene-gene interactions, equivalence of the cellular phenotype we observed with a published mouse model and confirmation of reduced protein abundance suggest the *MED24* variants in this line are pathogenic.

As expected, given poor neuroepithelial morphogenesis of cells from the GOSB2 patient line, further differentiation results in only sparse differentiation of PAX6-positive neural progenitor cells with few neurites positive for the neuronal marker TUJ1 (Supplementary Figure 13). In contrast, GOSB1 formed prominent neuronal rosettes equivalently to the control lines (Figure 5a). However, by day 35 of neuronal differentiation, GOSB1 cultures show diminished TUJ1 positivity, without a change in the proportion of cells positive for the progenitor marker SOX2, compared with the two control lines differentiated in parallel (Figure 5b-d). Poor neuronal maturation in cells from the GOSB1 line is clearly evident by day 45 of differentiation, when control lines form dense aggregates interconnected by axons while GOSB1 cells form sparse and

poorly-connected aggregates (Figure 5e,f). Thus, both the spina bifida patient-derived lines tested, in addition to *VANGL2-R353C* knock-in model, demonstrate quantifiable yet distinct abnormalities in neuroepithelial functions (Figure 5g).

Discussion

We present a multifaceted yet tractable and reproducible model of neuroepithelial morphogenesis which is sufficiently sensitive to identify NTD-associated dysfunctions in both forward and reverse genetic studies. All three of the NTD-associated models we compare – knock-in of a patient-identified *VANGL2* mutation and two patient-derived iPSC lines – identify abnormalities which are specific to that line, and which are not present in a panel of control lines tested. The abnormalities observed relate to apical constriction, apicobasal elongation, and neuronal maturation.

Neuroepithelial apical constriction is required for closure of both the cranial and spinal neural tube^{11,14,15,21}. Mouse and *Xenopus* models establish that expression of PCP signalling components enhances apical constriction^{20,23,65} but, to our knowledge, this had never been shown in a human system and no human genetic mutations have been linked to apical constriction as a likely pathogenic mechanism. The mechanisms by which *VANGL2* promotes apical localisation and activation of myosin²⁰ remain incompletely understood. They may include both PCP-specific functions of *VANGL2* equivalent to those originally identified for its orthologue in *Drosophila*, and potentially vertebrate-specific roles^{70,71}. The neuroepithelial model presented here does not produce planar features commonly used as characteristic readouts of PCP signalling *in vivo*^{26,40}. Nonetheless, our observation of increasing *VANGL2* poly-phosphorylation suggests ligand-induced pathway activation during differentiation³⁵. This contrasts with decreasing *VANGL2* phosphorylation previously reported during *in vitro* differentiation of lactogenic cells⁷⁰.

The diminished apical constriction phenotype we document following *VANGL2-R535C* mutation occurs despite achieving wildtype-equivalent *VANGL2* expression. Nonetheless, comparison with mouse embryos globally lacking *Vangl2* suggests *VANGL2-R535C* is sufficient to explain all of the dilation in apical area caused by deletion of this protein. Other mutations in the protein's C-terminus domain which disrupt *VANGL2* function sufficiently to stop neural tube closure have previously been reported in mice^{20,39,40}. *VANGL2*'s C-terminus contains the prickle-binding domain (directly affected by the R353C mutation) and PDZ domain, which interacts with other components of the PCP pathway including *SCRIB*⁷². *SCRIB* also enhances apical constriction in mice^{15,73}.

We observe that apical constriction correlates with apicobasal epithelial thickening during iPSC-to-neuroepithelial differentiation. This inter-relation is well-established in *Drosophila* ventral furrow formation^{74,75}, and can be replicated following optogenetic induction of apical constriction in cultured mouse cells⁷⁶. In mice, neuroepithelial apicobasal thickness is spatially patterned with shorter cells at the midline, under the influence of SHH signalling^{14,77,78}. Apicobasal thickness of the cranial neural folds increases from ~25 µm at E7.75 to ~50 µm at E8.5⁷⁹; closely paralleling the elongation between days 2 and 8 of differentiation in our protocol. The rate of thickening is non-uniform, with the greatest increase occurring during elevation of the neural folds⁸⁰, also paralleled in our model by the rapid increase in thickness between days 4-6 as apical areas decrease. Elevation requires neuroepithelial apical constriction and these cells' apical area decreases between E7.75 and E8.5 in mice⁷⁹, but we and others have recently shown that this reduction is both region and sex-specific^{14,81}. Specifically, apical constriction occurs in the lateral (future dorsal) neuroepithelium: this corresponds with the identity of the cells generated by the dual SMAD inhibition model we use⁵⁶. More recently, Brooks et al⁸² showed that the rapid reduction in apical area from E8-E8.5 is associated with cadherin switching from CDH1 (E-cadherin) to CDH2 (N-cadherin). This is also directly paralleled in our human system, which shows low-level co-expression of CDH1 and CDH2 at day 4 of differentiation, immediately before apical area shrinks and apicobasal thickness increases.




Figure 5. Diminished neuronal maturation suggests post-neurulation deficit of an iPSC line derived from a patient with spina bifida.

a, Representative confocal images of GOC1, and GOSB1 neuronal rosette cultures (day 20) immunolabelled against PAX6 and F-actin. Scale = 100 μ m. **b**, Representative immunofluorescence panel of SOX2 and TUJ1 immunofluorescence of day 30 cultures, showing GOC1, GOC2, and GOSB1 lines. Scale = 50 μ m. **c**, **d**, Dot plot representing TUJ1/DAPI staining intensity (**c**) and the percentage of nuclei positive for SOX2 (**d**). Values were calculated in three independent replicates shown as individual dots and the average is shown with the bars. **e**, Widefield images of day 45 GOC1 and GOSB1 neuronal cultures immunolabelled for TUJ1. Scale = 200 μ m. **f**, Box plot representing the TUJ1 positive area quantified across three independent cultures of GOC1 and GOSB1 cell lines, on day 45 of differentiation. P values from one-way ANOVA with post-hoc Bonferroni (***: $p \leq 0.001$, **: $p \leq 0.01$, n.s.: not significant). **g**, Summary of patient-associated hiPSCs lines used in this study along with the stage of failure to form a functional neuroepithelium or undergo mature neuronal formation in vitro.

Conservation of cells' volume has been suggested to link apical constriction with apicobasal elongation⁷⁵. However, we provide two lines of evidence that this inter-relation during neuroepithelial differentiation is not simply due to volume conservation. Firstly, cell volume decreases during neuroepithelial differentiation as thickness increases. Secondly, neither epithelial thickness nor cell volume are significantly altered in *VANGL2-R535C* neuroepithelial cells with diminished apical tension. Mechanistic separability of apical constriction and apicobasal elongation is consistent with biomechanical modelling of *Xenopus* neural tube closure showing that both are independently required for tissue bending⁶¹. Nonetheless, neuroepithelial apical constriction and apicobasal elongation are co-regulated in mouse models: for example, deletion of *Nuak1/2*⁸³, *Cfl1*⁸⁴, and *Pten*⁷⁹ all produce shorter neuroepithelium with larger apical areas. Neuroepithelial cells of the GOSB2 line described here, which has partial loss of MED24, similarly produces a thinner neuroepithelium with larger apical areas. Although apical areas were not analysed in mouse models of *Med24* deletion, these embryos also have shorter and non-pseudostratified neuroepithelium⁶⁸.

Our GOSB2 line – which retains readily detectable MED24 protein – is clearly less severe than the mouse global knockout of this gene, and the clinical features of the patient from which this line was derived are milder than the phenotype of knockout embryos⁶⁸. Mouse embryos lacking one of *Med24*'s interaction partners in the mediator complex, *Med1*, also have thinner neuroepithelium and diminished neuronal differentiation but successfully close their neural tube⁸⁵. As general regulators of polymerase activity, MED proteins have the potential to alter the timing or level of expression of many other genes, including those already known to influence pseudostratification or apicobasal elongation. MED depletion also causes redistribution of cohesion complexes⁸⁶ which may impact chromatin compaction, reducing nuclear volume during differentiation. MED family proteins are increasingly implicated in human neural tube defects: *MED12* and *MED13L* likely pathogenic variants have been reported in patients^{9,87}. Their functions during neural tube closure, including through known interactions with Wnt and PCP pathways⁸⁸, remain incompletely understood and future work will be needed to determine whether *MED24* mutation is the only genetic change relevant to neuroepithelial morphogenesis in GOSB2. MED protein contributions to neurogenesis and neuronal maturation are more well-established^{85,89–91}.

Another limitation of our model, shared by many *in vitro* systems, is the poor ability to replicate maternal environmental influences. For example, the validated cell culture media used for this model contain 3.4 mg/L folic acid instead of folate. This may mask NTD predispositions caused by maternal folate deficiency or genetically impaired placental transport, while accentuating cellular deficiencies which diminish folic acid conversion into a one-carbon donor⁹². We cannot exclude *in vitro* accentuation of the cellular phenotype of the GOSB2 line, as it is difficult to imagine that such severe failure of neuroepithelial morphogenesis would produce a sufficiently normal spinal cord to benefit from fetal surgery performed on the patient these cells were derived from.

Alternatively, compensation may be possible *in vivo*, potentially through interactions between tissue types which promote robustness of morphogenesis.

Some of these limitations, potentially including inclusion of environmental risk factors, can be addressed by using alternative iPSC-derived models^{93,94}. For example, if patients have suspected causative mutations in genes specific to the surface (non-neural) ectoderm, such as *GRHL2/3*, 3D models described by Karzbrun et al⁴⁹ or Huang et al⁹⁵ may be informative. Characterisation of surface ectoderm behaviours in those models is currently lacking. These models are particularly useful for high-throughput screens of induced mutations⁹⁵, but their reproducibility between cell lines, necessary to compare patient samples to non-congenic controls, remains to be validated. Spinal cell identities can be generated in human spinal cord organoids, although these have highly variable morphologies^{96,97}. As such, each iPSC model presents limitations and opportunities, to which this study contributes a reductionist and highly reproducible system in which to quantitatively compare multiple neuroepithelial functions.

A key benefit of our system is the natural progression from cell functions relevant to neurulation, to neurogenesis. Others previously reported that iPSC lines derived from individuals who have spina bifida are less able to differentiate into neurons than those from healthy controls⁹⁸. This is

consistent with our findings in the GOSB1 patient-derived line. Although gene rescue experiments are beyond the scope of this study, potentially deleterious variants identified in the GOSB1 patient line, including a *ZIC5* variant, may impair neuronal development. The reduction in TUJ1 positive cells observed in this line compared with non-congenic controls is at a point in differentiation which is highly comparable between individuals and produces deep-layer cortical neurons⁹⁹. Individuals with spina bifida commonly have thinning of the neocortex and other supratentorial brain abnormalities¹⁰⁰. What is less clear is whether diminished neurogenesis, which normally occurs after closure of the neural tube, may relate to causation of NTDs. The converse – that open spina bifida impairs neural development – is directly supported by experimental evidence¹⁰¹. Nonetheless, impaired neuronal differentiation of patient-derived iPSC lines raises the potential for shared genetic/epigenetic causation of the spinal lesion and cortical brain abnormalities, potentially compounded by abnormalities in cerebrospinal fluid drainage and amniotic fluid exposure.

In summary, our findings in a human neuroepithelial model corroborate animal studies identifying diminished apical constriction as a cause of NTDs, implicate *VANGL2* acting upstream of myosin phosphorylation in this behaviour, identify diminished neuroepithelial thickness in a patient-specific disease model and corroborate the importance of MED family proteins known to enhance this process as an emerging genetic contributor to human NTDs. The multi-genic nature of neural tube defect susceptibility, compounded by uncontrolled environmental risk factors (including maternal age and parity¹⁰²), mean that patient-derived iPSC models are unlikely to provide mechanistic insight. They do provide personalised disease models which we anticipate will enable functional validation of genetic diagnoses for patients and their parents' recurrence risk in future pregnancies, and may eventually stratify patients' postnatal care. We also envision this model will enable quality control of patient-derived cells intended for future autologous cell replacement therapies, as is being developed in post-natal spinal cord injury¹⁰³. Thus, the highly reproducible modelling platform we evaluate – which is robust to differences in iPSC reprogramming method, sex and ethnicity – represents a valuable tool for future mechanistic insights and personalised disease modelling applications.

Materials and methods

Human iPSC culture maintenance

All iPSCs lines were grown in E8 medium (ThermoFisher, A1517001), using 0.5% Matrigel Growth Factor Reduced (Corning, 354277) coated plates, according to a previously published protocol¹⁰⁴. Cells were routinely grown in 6 well plates (SARSTEDT, 833920300), unless otherwise stated. E8 medium was fully replaced daily. At ~80% confluency cells were washed with PBS without $\text{CaCl}_2/\text{MgCl}_2$ (ThermoFisher, 14190094) and dissociated with 0.5 mM EDTA (ThermoFisher, 15575020) for 5 min. Cells were resuspended in E8 medium and re-plated at a 1:10 split ratio. All cell lines were tested monthly for mycoplasma contamination, using the MycoAlert[®] kit (Lonza, LT07-318). A summary with the characteristics and reprogramming technologies of the hiPSCs lines used on this study can be found in Table 1 [↗](#).

Unless otherwise stated, for each iPSC line three independently differentiated plates were generated and analysed, with each plate representing a separate differentiation experiment performed on different days. For patient-specific iPSC lines, one independent iPSC line was obtained per patient following microfluidic mmRNA reprogramming⁵⁷.

VANGL2 knock-in cell line generation

The selection of the mutation was made according to a previously identified gene alteration in a patient described as having anencephaly with occipital and cervical spina bifida⁴⁶. The specific point mutation was found in heterozygosity and was located on chromosome 1, at nucleotide 160,421,174 in the genomic sequence (Supplementary Figure 5 [↗](#)). Although other *Vangl2* mutations have been found to exert dominant negative effects¹⁰⁵, we generated homozygous mutant lines to facilitate interpretation of results obtain. In collaboration with SYNTHGO, an

Cell line name	Designation [#]	Source	Karyotype	Reprogramming method
SFC086-03-01	iPSC2	Livesey Lab ¹⁷	46, XX	Non-integrating Sendai virus
HO193b	iPSC1, GOC1	NIHR GOSH BRC*	46, XY	Microfluidic mmRNAs
HO471b	GOSB1	NIHR GOSH BRC*	46, XX	Microfluidic mmRNAs
HO220	GOC2	NIHR GOSH BRC*	46, XY	Microfluidic mmRNAs
HO541	GOSB2	NIHR GOSH BRC*	46, XY	Microfluidic mmRNAs
802-30F, parental	iPSC3, WT	SYNTHGO	46, XX	StemRNA™ 3 rd Gen
802-30F, VANGL2-R353C, clone E2	KI-1	SYNTHGO	46, XX	StemRNA™ 3 rd Gen
802-30F, VANGL2-R353C, clone F1	KI-2	SYNTHGO	46, XX	StemRNA™ 3 rd Gen

[#] Shorthand nomenclature used in this paper for simplicity. *National Institute of Health Research Great Ormond Street Hospital Biomedical Research Centre

Table 1. hiPSCs line information.

established hiPSC line 802-30F was genetically engineered to introduce a homozygous point mutation by replacing a cytosine (C) with a thymine (T) (CGC>TGC), at a specific genetic locus. After high knock-in efficiency was confirmed, specific sgRNA with Cas9 were electroporated to the cells. *VANGL2* knock-in lines were generated using CRSIPR-Cas9 homology directed repair editing by Synthego (SO-9291367-1). The guide sequence was AUGAGCGAAGGGUGCGCAAG and the donor sequence was CAATGAGTACTACTATGAGGAGGCTGAGCATGAGCGA
AGGGTGTGCAAGAGGAGGGCCAGGTGGGTCCCTGGGGGAGAAGAGGAGAG.

Sequence modification was confirmed by Sanger sequencing before delivery of the modified clones, and Sanger sequencing was repeated after expansion of the lines (Supplementary Figure 5) as well as SNP arrays (Illumina iScan, not shown) confirming genomic stability. For the generation of the isogenic control line (WT), the cells were electroporated with SpCas9 only and confirmed to be unedited at target locus.

Approximately two weeks later the cells colonies have expanded and genotyping of the pool of clones was undertaken. Individual clones were then isolated and clonally expanded to confirm the presence of the knock-in genetic alteration. Those clones positive for the genetic alteration were further Sanger sequenced to confirm stable *VANGL2* editing.

Adherent neural induction protocol

Direct differentiation of hiPSCs to neuroepithelial sheets was as we previously reported¹⁷. Briefly, hPSCs were lifted with EDTA and plated at 100% confluency, ~300,000 cells/cm², in E8 medium. It is critical to ensure that 100 % confluency is reached at seeding (considered ‘day 1’). After 24 hours, cells were washed twice with PBS without CaCl₂/MgCl₂ and the medium was replaced with 2 ml of neural maintenance media (NMM, see Table 2), supplemented with 1 μM Dorsomorphin (Tocris, 3093) and 10 μM SB431542 (Tocris, 1614). NMM with these supplements is referred as neural induction medium (NIM) and was refreshed daily until day 8. At that timepoint the cultures were terminated or passaged for neuronal differentiation.

Neuronal differentiation was performed as previously described⁵⁶. The neuroepithelial sheets were passaged at day 8, using Dispase (ThermoFisher, 17105041) for 15-20 minutes at 37°C. After washing with PBS, neuroepithelial clumps were plated on 1% Matrigel-coated 6-wells in NIM, ensuring sufficiently sparse seeding to give clumps space to form rosettes. After 24 hours of passaging, the medium was changed to NMM supplemented daily with 20 ng/ml of FGF2 (PeproTech, AF-100-18B) for the next four days. After day 12, neural rosettes were passaged to 1% Matrigel coated plates, using Dispase. NMM was then changed every 48 hours. This process was repeated at least three-times, when confluency reaches 80 %, until day 25 when the neural progenitor cells mature. At that stage, once the confluency reached 80 %, cells were passaged with Accutase (Sigma, A6964) to dissociate the rosettes into single cells. At that stage (~day 30) cells can be cryopreserved or plated for the last time at 25,000-75,000 cells/cm² on Laminin-521 (Gibco, A29249) coated plates.

Generation of *Vangl2* knockout mouse embryos

Studies were performed under the regulation of the UK Animals (Scientific Procedures) Act 1986 and the National Centre for the 3Rs’ Responsibility in the Use of Animals for Medical Research (2019). Mice were mated overnight, and the next morning was considered to be E0.5 if a plug was found. *Vangl2* knockout mouse embryos were as previously described¹⁰⁶.

Immunofluorescent staining and confocal microscopy

Adherent cultures were stained for a maximum of 20 minutes in cold 4% paraformaldehyde (PFA) and immunofluorescent staining as previously described¹⁷. Primary antibodies used were rabbit anti-ROCK (Abcam antibody ab45171), rabbit anti-Ser19 pMLC (Cell Signalling Technology antibody #3671), rabbit anti-SOX2 (Merck antibody ab5603), mouse anti-CDH2 (Cell Signalling Technology antibody #14215), mouse anti-Lamin A/C (Santa Cruz antibody sc7292), goat anti-Lamin B1 (Santa Cruz antibody sc6216), rabbit anti-ZO1 (Thermo Fisher Scientific antibody #40-2200), goat anti-scribble (Santa Cruz antibody sc-11049), rat anti-VANGL2 (Merck antibody,

Product	Volume (ml)	Company	Cat. Number	Storage (°C)
Solution A (500ml):				
2-Mercaptoethanol	1	Gibco	21985-023	4
DMEM/F12+Glutamax	481.25	Gibco	A15169-01	4
Insulin	0.25	Sigma	19278	4
N2 supplement (100x)	5	Gibco	17502-048	-20
Non-Essential amino Acids	5	Gibco	11140-050	4
Penicillin/Streptomycin	2.5	Gibco	15140-122	-20
Sodium Pyruvate	5	Sigma	S8636	4
Solution B (500ml):				
B27-supplement	10	Gibco	17504-044	-20
L-Glutamine	5	Gibco	25030-024	-20
Neurobasal	482.5	Gibco	12348-017	4
Penicillin/Streptomycin	2.5	Gibco	15140-122	-20

Table 2. Composition of neural maintenance medium.

MABN750), rabbit anti-Pax6 (Biolegend antibody 901301), and mouse anti-TUJ1 (BioLegend MMS-435P), and detected with Alexa Fluor™ conjugated secondary antibodies (Thermo Fisher Scientific). All primary and secondary antibodies were used in 1:200 and 1:500 dilution, respectively. Nuclei were labelled with DAPI (Severn Biotech Ltd 17057) and F-actin was labelled with Alexa Fluor™-647 conjugated phalloidin (Thermo Fisher Scientific). Confocal salt and pepper noise was removed using a ‘remove outliers’ filter and linear adjustments to brightness and contrast were applied to all parts of each figure panel equally.

Confocal images were captured on a Zeiss Examiner LSM880 confocal, using a 20x/NA1.0 Plan Apochromat dipping objective with AiryScan Fast. Widefield images of the neural rosettes and neuronal cultures were captured on a Zeiss Observer inverted using 10x/NA0.45 objective or a Nikon Ti2 Eclipse widefield microscope using 10x/NA0.30 or 20x/NA0.45 Plan Apochromat λ D objectives.

Laser ablations and live imaging

Annual laser ablations were performed as previously reported^{11,20} on day 8 neuroepithelial sheets. Briefly, cells were homogenously stained with CellMask membrane dye (Invitrogen, C10046) and a single apical z-slice was selected for the target region. The ablation circle was randomly placed in the stained neuroepithelial sheet and three ablations in different fields of view were performed per dish then averaged (no predictable change in tension was observed between repeated ablations). The percentage reduction in cell area within the ablated annulus immediately after ablation was quantified. The imaging order for each cell line was alternated between each independent replicate to ensure no bias in the analysis and recoils were analysed blinded to genotype/treatment.

For live-imaging sessions, day 8 neuroepithelial sheets were stained for 5 minutes with CellMask Deep Red Actin Tracking stain (ThermoFisher, A57245) in NIM. Imaging was performed with the Zeiss LSM880 confocal microscope using 20x/NA1.0 Plan Apochromat dipping objective. The microscope chamber was pre-warmed at 37 °C and CO₂ was set at 5 %. The water-immersive objective was cleaned with 70 % ethanol solution and let to air dry to remove any potential contaminants. A plexiglass chamber was assembled around the culture plate to maintain stable culture condition. Damp cotton wool was put in the plexiglass set up to create a humidified chamber and avoid media evaporation. ZEN Black v2.3 was used to operate the microscope and capture images. Apical region images were acquired every 5 minutes.

Particle intensity velocimetry (PIV) analysis

Particle Image Velocimetry (PIV) examined the flow of apical areas of day 8 neuroepithelial sheets after laser ablations. Briefly, we identify changes in pixel flow before and after the ablation. For the PIV analysis used in this report a pre-installed plug in FIJI was used¹⁰⁷. The analysis considers the displacement of pixels within a specific region, termed ‘interrogation window’. This area in the present study was specified between two frames, before and immediately after the circular laser ablation. For the analysis a ‘Pure Denoise’ filter (Cycle-spins: 4, Multiframe: 2) was used to ensure that non-specific random noise is not interpreted as movement.

Quantitative cell morphology analysis

Apical area analyses were performed in F-actin stained neuroepithelial sheets, using the polygon selection tool in FIJI and outlining the apical cap of individual cells and saving them as ROIs. At least 100 contiguous cells were analysed from each image.

Epithelial apicobasal thickness, confocal images were optically resliced and their cross-section outline manually annotated. Thickness was calculated using the ‘bounding rectangle’ (width) tool in ImageJ/Fiji. This was performed in three images across each dish and the average height was calculated for each culture.

For fluorescent signal polarisation analysis, the plot profile command in ImageJ/FIJI was applied to an optically-resliced section of equal thickness within each dataset.

TUJ1 and SOX2 neuronal quantification

For the quantification of TUJ1+ axons of neural progenitor, the total area of axons was quantified relative to the area imaged. The TUJ1 signal was binarized using the ‘Threshold’ command, and the total area of the axons was summed. Finally, the TUJ1+ area was normalised to the total number of cells per field of view.

For the quantification of SOX2 nuclear marker in neuronal progenitor cultures, a multi-step pipeline was used. Initially, all nuclei were identified in the DAPI-stained channel and using the command ‘Find Maxima’ in FIJI. A binarized image was generated, with individual points within each nucleus. Each point was enlarged and used to generate a ROI within each nucleus. The individual points were used as a reference to quantify the SOX2 intensity within each cell. A threshold was set manually after identifying the nucleus with the lowest positive signal. Finally, the percentage for positive nuclei was calculated after subtracting the total cell numbers with the positive proportion and dividing by the overall cell number.

Western blotting and quantification

Western blotting was performed as previously described¹⁰⁸. Neuroepithelial cells were lysed on ice for 30 min in 50 mM Tris Base pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.02% Sodium Azide, 1x protease inhibitor cocktail (Merck Life Science UK Ltd), 1 mM sodium orthovanadate, 25 mM sodium fluoride. The protein concentration was determined using Pierce BCA Protein Assay kits (Thermo Fisher). Proteins were resolved by SDS-PAGE using 10-12% polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked in TBS (15.4 mM Trizma-HCL, 4.62 mM Tris-base, 150 mM NaCl, pH 7.6) containing 10% w/v milk powder (Merck Life Science UK Ltd). Membranes were incubated with primary antibody overnight and then with horseradish peroxidase (HRP)-conjugated secondary antibodies (Agilent Technologies, Stockport, UK) for 1 hour. Primary antibodies were used rabbit anti-pVangl2 (Merck antibody SAB5701946), mouse anti-NANOG (Abcam antibody ab173368), rabbit anti-OCT4 (Abcam antibody ab19857), mouse anti-CDH1 (R&D FAB18381A), mouse anti-GAPDH (Merck antibody MAB374), rabbit anti-MED24 (BETHYL antibody A301-472A). HRP was detected using ECL Prime (Cytiva, Amersham, UK). To strip and re-probe, membranes were incubated in 0.2 M NaOH for 20 min at 37 °C and then 20 min at room temperature before re-blocking and re-use.

For the quantification of western blot films, the band area method was applied using ImageJ/FIJI. A box was drawn around the bands and after ensuring all bands fit within it, and the intensity profile was plotted. The total area between the line graph and x axis, after removing background, was quantified for each sample. The protein level was normalised to the housekeeping protein, LMNB or GAPDH. The normalised protein levels were compared between samples, and a control value was normalised to 1. Protein quantifications were performed in paired replicates or in three independent cell lines.

Whole exome sequencing

Approximately 500 ng of DNA from each cell line, namely GOC1, GOC2, GOSB1, and GOSB2, were purified. The subsequent steps of fragmentation, library preparation, Illumina sequencing were performed using established pipelines by Azenta, UK. Upon receipt of the samples, a quality control (QC) screening was executed, and all samples successfully pass the QC threshold including concentration and maintaining high DNA integrity number (DIN, >7.8). FASTQ data QC, genomic alignment, variant calling and annotation was also performed by Azenta, UK. For all samples, >97.5% of target regions achieved a read depth ≥20X. Variants were annotated using the Sequence Ontology consensus terms. The following were considered to have a high impact: transcript_ablation (SO:0001893), splice_acceptor_variant (SO:0001574), splice_donor_variant (SO:0001575), stop_gained (SO:0001587), frameshift_variant (SO:0001589), stop_lost (SO:0001578), start_lost (SO:0002012), and transcript_amplification (SO:0001889).

NTD associated gene sorting workflow

Lists of genes with annotated variants in GOSB1 and GOSB2 were compared with GOC1 and GOC2. Only variants not shared with GOC1/2 were considered in order to eliminate batch effects and very common variants. Each of resulting gene lists was then cross-referenced with the most current compilation of mouse models associated with NTDs, as documented in Lee and Gleeson⁵. Two additional gene lists were generated based on searches in ClinVar database for entries linked to "Neural Tube Defect" and "Spina Bifida" (Supplementary Table 1 [↗](#)). Collectively, these identified a subset of variant genes associated with NTDs. These were subsequently filtered by sequence ontology severity score, and the allele frequencies of high impact variants was determined using gnomAD v4.1.0¹⁰⁹.

Statistical analysis and reproducibility

Comparisons between two groups were by Student's t-test accounting for homogeneity of variance in SPSS (IBM Statistics 25). Comparison of multiple groups was first tested for normality and homogeneity of variance in Origin 2020 (Origin Labs). According to the result if samples were normally distributed an ANOVA test was performed, while for non-parametric datasets a Kruskal-Wallis ANOVA was used in Origin 2020 (Origin Labs). Post-hoc pairwise analysis was performed to determine the statistical significance. P values <0.05 were considered statistically significant. All graphs were generated in Origin 2020. Replicates were defined as technical replicates (same iPSC line cultured at the same time) or biological replicates (different iPSC lines or same line cultured independently). In the case of VANG2 knock-in lines, two clones were compared with their congenic control line. To avoid bias, blinding and randomisation was performed where possible by asking a lab member to rename copied files, without disclosing cell line information prior to analysis. However, changes of neuroepithelial thickness across time points days was too dramatic to not know which day was analysed and morphological differences of GOSB3 also precluded blinding.

Data availability

"Ampartzidis_SourceData.xlsx" contains the numerical data used to generate graphs in the figures.

Acknowledgements

The authors would like to thank Prof F Livesey and Dr F Paonessa for their assistance in establishing the dual-SMAD inhibition protocol in our lab and provision of SFC086-03-01 as a reference line. We thank Jessica Reeves for technical assistance with western blots, Louis Hamilton for help with apical area segmentation, Dr Teresa Pereira da Silva for scientific discussions and cell culture assistance, Dr Timo N. Kohler and Clara Munger for their critical reading of the manuscript, and Dr Dale Moulding for assistance with imaging. IA was funded by the NIHR GOSH Biomedical Research Centre. Views expressed in this manuscript are solely those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. GLG acknowledges funding from the Royal Society (RG\R2\232082), Rosetrees (2023\100266), NC3Rs (NC/Y50063X/1) and Wellcome Trust (211112/Z/18/Z).

Additional information

Author contributions

IA, EMT, YG, AK and GLG performed and analysed experiments. GLG, PDC and NE conceived the study and designed experiments with IA. GLG, PDC and IA secured funding. GLG, PDC, NE and EM supervised staff. GLG and IA wrote the manuscript with input from all co-authors.

Funding

Funder	Grant reference number	Author
Royal Society	RG\R2\232082	Gabriel L Galea
Rosetrees Trust	2023\100266	Gabriel L Galea
National Centre for the Replacement Refinement and Reduction of Animals in Research	NC/Y50063X/1	Gabriel L Galea
Wellcome Trust	https://doi.org/10.35802/211112	Gabriel L Galea
Great Ormond Street Hospital for Children		Gabriel L Galea

Author ORCID iDs

Yashica Gupta: <https://orcid.org/0009-0005-1056-6993>

Eirini Maniou: <https://orcid.org/0000-0001-9419-7374>

Gabriel L Galea: <https://orcid.org/0000-0003-2515-1342>

Additional files

[Supplementary Figures](#) 

[Supplementary Tables 1-3](#) 

References

- Zaganjor I.**, et al. (2016) Describing the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. *PLoS One* **11**:e0151586 <https://doi.org/10.1371/journal.pone.0151586>
- Santos C**, Marshall AR, Murray A, Metcalfe K, Narayan P, de Castro SCP, Maniou E, Greene NDE, Galea GL, Copp AJ (2024) Spinal neural tube formation and tail development in human embryos. *eLife* **12**:RP88584
- Nikolopoulou E.**, Galea G. L., Rolo A., Greene N. D., Copp A. J (2017) Neural tube closure: cellular, molecular and biomechanical mechanisms. *Development* **144**:552-566 <https://doi.org/10.1242/dev.145904>
- Chen Z.**, et al. (2018) Threshold for neural tube defect risk by accumulated singleton loss-of-function variants. *Cell Res* **28**:1039-1041 <https://doi.org/10.1038/s41422-018-0061-3>
- Lee S.**, Gleeson J. G (2020) Closing in on Mechanisms of Open Neural Tube Defects. *Trends Neurosci* **43**:519-532 <https://doi.org/10.1016/j.tins.2020.04.009>
- Finnell R. H.**, et al. (2021) Gene Environment Interactions in the Etiology of Neural Tube Defects. *Front Genet* **12** <https://doi.org/10.3389/fgene.2021.659612>
- Cao X.**, et al. (2020) Loss of RAD9B impairs early neural development and contributes to the risk for human spina bifida. *Hum Mutat* **41**:786-799 <https://doi.org/10.1002/humu.23969>
- Crane-Smith Z.**, et al. (2023) A non-coding insertional mutation of Grhl2 causes gene over-expression and multiple structural anomalies including cleft palate, spina bifida and encephalocele. *Hum Mol Genet* **32**:2681-2692 <https://doi.org/10.1093/hmg/ddad094>
- Tian T.**, et al. (2021) Somatic and de novo Germline Variants of MEDs in Human Neural Tube Defects. *Front Cell Dev Biol* **9** <https://doi.org/10.3389/fcell.2021.641831>
- Maniou E.**, et al. (2023) Caudal Fgfr1 disruption produces localised spinal mis-patterning and a terminal myelocystocele-like phenotype in mice. *Development* **150** <https://doi.org/10.1242/dev.202139>

- 11 **Butler M. B.**, et al. (2019) Rho kinase-dependent apical constriction counteracts M-phase apical expansion to enable mouse neural tube closure. *J Cell Sci* **132** <https://doi.org/10.1242/jcs.230300>
- 12 **McShane S. G.**, et al. (2015) Cellular basis of neuroepithelial bending during mouse spinal neural tube closure. *Dev Biol* **404**:113-124 <https://doi.org/10.1016/j.ydbio.2015.06.003>
- 13 **Ferreira M. A.**, Despin-Guitard E., Duarte F., Degond P., Theveneau E (2019) Interkinetic nuclear movements promote apical expansion in pseudostratified epithelia at the expense of apicobasal elongation. *PLoS Comput Biol* **15**:e1007171 <https://doi.org/10.1371/journal.pcbi.1007171>
- 14 **Brooks E. R.**, Islam M. T., Anderson K. V., Zallen J. A (2020) Sonic hedgehog signaling directs patterned cell remodeling during cranial neural tube closure. *eLife* **9** <https://doi.org/10.7554/eLife.60234>
- 15 **Lesko A. C.**, Keller R., Chen P., Sutherland A (2021) Scribble mutation disrupts convergent extension and apical constriction during mammalian neural tube closure. *Dev Biol* **478**:59-75 <https://doi.org/10.1016/j.ydbio.2021.05.013>
- 16 **Smith J. L.**, Schoenwolf G. C., Quan J (1994) Quantitative analyses of neuroepithelial cell shapes during bending of the mouse neural plate. *J Comp Neurol* **342**:144-151 <https://doi.org/10.1002/cne.903420113>
- 17 **Ampartzidis I.**, et al. (2023) Synchronisation of apical constriction and cell cycle progression is a conserved behaviour of pseudostratified neuroepithelia informed by their tissue geometry. *Dev Biol* **494**:60-70 <https://doi.org/10.1016/j.ydbio.2022.12.002>
- 18 **Martin A. C.**, Goldstein B (2014) Apical constriction: themes and variations on a cellular mechanism driving morphogenesis. *Development* **141**:1987-1998 <https://doi.org/10.1242/dev.102228>
- 19 **Escuin S.**, et al. (2015) Rho-kinase-dependent actin turnover and actomyosin disassembly are necessary for mouse spinal neural tube closure. *J Cell Sci* **128**:2468-2481 <https://doi.org/10.1242/jcs.164574>
- 20 **Galea G. L.**, et al. (2021) Cell non-autonomy amplifies disruption of neurulation by mosaic Vangl2 deletion in mice. *Nat Commun* **12**:1159 <https://doi.org/10.1038/s41467-021-21372-4>
- 21 **McGreevy E. M.**, Vijayraghavan D., Davidson L. A., Hildebrand J. D (2015) Shroom3 functions downstream of planar cell polarity to regulate myosin II distribution and cellular organization during neural tube closure. *Biol Open* **4**:186-196 <https://doi.org/10.1242/bio.20149589>
- 22 **Nishimura T.**, Honda H., Takeichi M (2012) Planar cell polarity links axes of spatial dynamics in neural-tube closure. *Cell* **149**:1084-1097 <https://doi.org/10.1016/j.cell.2012.04.021>
- 23 **Kowalczyk I.**, et al. (2021) Neural tube closure requires the endocytic receptor Lrp2 and its functional interaction with intracellular scaffolds. *Development* **148** <https://doi.org/10.1242/dev.195008>
- 24 **Ossipova O.**, et al. (2014) Role of Rab11 in planar cell polarity and apical constriction during vertebrate neural tube closure. *Nat Commun* **5**:3734 <https://doi.org/10.1038/ncomms4734>
- 25 **Boutros M.**, Paricio N., Strutt D. I., Mlodzik M (1998) Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. *Cell* **94**:109-118 [https://doi.org/10.1016/s0092-8674\(00\)81226-x](https://doi.org/10.1016/s0092-8674(00)81226-x)
- 26 **Adler P. N** (1992) The genetic control of tissue polarity in *Drosophila*. *Bioessays* **14**:735-741 <https://doi.org/10.1002/bies.950141103>
- 27 **Gubb D.**, Garcia-Bellido A (1982) A genetic analysis of the determination of cuticular polarity during development in *Drosophila melanogaster*. *J Embryol Exp Morphol* **68**:37-57
- 28 **Murdoch J. N.**, Doudney K., Paternotte C., Copp A. J., Stanier P (2001) Severe neural tube defects in the loop-tail mouse result from mutation of *Lpp1*, a novel gene involved in floor plate specification. *Hum Mol Genet* **10**:2593-2601 <https://doi.org/10.1093/hmg/10.22.2593>
- 29 **Kibar Z.**, et al. (2001) Ltap, a mammalian homolog of *Drosophila* Strabismus/Van Gogh, is altered in the mouse neural tube mutant Loop-tail. *Nat Genet* **28**:251-255 <https://doi.org/10.1038/90081>
- 30 **Wallingford J. B.**, et al. (2000) Dishevelled controls cell polarity during *Xenopus* gastrulation. *Nature* **405**:81-85 <https://doi.org/10.1038/35011077>

- 31 Rothbacher U., et al. (1995) Functional conservation of the Wnt signaling pathway revealed by ectopic expression of *Drosophila* dishevelled in *Xenopus*. *Dev Biol* **170**:717-721 <https://doi.org/10.1006/dbio.1995.1249>
- 32 Aw W. Y., Devenport D (2017) Planar cell polarity: global inputs establishing cellular asymmetry. *Curr Opin Cell Biol* **44**:110-116 <https://doi.org/10.1016/j.ceb.2016.08.002>
- 33 Yu H., et al. (2010) Frizzled 1 and frizzled 2 genes function in palate, ventricular septum and neural tube closure: general implications for tissue fusion processes. *Development* **137**:3707-3717 <https://doi.org/10.1242/dev.052001>
- 34 Murdoch J. N., et al. (2014) Genetic interactions between planar cell polarity genes cause diverse neural tube defects in mice. *Dis Model Mech* **7**:1153-1163 <https://doi.org/10.1242/dmm.016758>
- 35 Yang W., et al. (2017) Wnt-induced Vangl2 phosphorylation is dose-dependently required for planar cell polarity in mammalian development. *Cell Res* **27**:1466-1484 <https://doi.org/10.1038/cr.2017.127>
- 36 Humphries A. C., et al. (2023) A Van Gogh/Vangl tyrosine phosphorylation switch regulates its interaction with core Planar Cell Polarity factors Prickle and Dishevelled. *PLoS Genet* **19**:e1010849 <https://doi.org/10.1371/journal.pgen.1010849>
- 37 Ybot-Gonzalez P., et al. (2007) Convergent extension, planar-cell-polarity signalling and initiation of mouse neural tube closure. *Development* **134**:789-799 <https://doi.org/10.1242/dev.000380>
- 38 Nychyk O., et al. (2022) Vangl2-environment interaction causes severe neural tube defects, without abnormal neuroepithelial convergent extension. *Dis Model Mech* **15** <https://doi.org/10.1242/dmm.049194>
- 39 Lopez-Escobar B., et al. (2018) The non-canonical Wnt-PCP pathway shapes the mouse caudal neural plate. *Development* **145** <https://doi.org/10.1242/dev.157487>
- 40 Galea G. L., et al. (2018) Vangl2 disruption alters the biomechanics of late spinal neurulation leading to spina bifida in mouse embryos. *Dis Model Mech* **11** <https://doi.org/10.1242/dmm.032219>
- 41 Baumholtz A. I., et al. (2017) Claudins are essential for cell shape changes and convergent extension movements during neural tube closure. *Dev Biol* **428**:25-38 <https://doi.org/10.1016/j.ydbio.2017.05.013>
- 42 Doudney K., et al. (2005) Analysis of the planar cell polarity gene Vangl2 and its co-expressed paralogue Vangl1 in neural tube defect patients. *Am J Med Genet A* **136**:90-92 <https://doi.org/10.1002/ajmg.a.30766>
- 43 De Marco P., et al. (2014) Planar cell polarity gene mutations contribute to the etiology of human neural tube defects in our population. *Birth Defects Res A Clin Mol Teratol* **100**:633-641 <https://doi.org/10.1002/bdra.23255>
- 44 Iliescu A., Gravel M., Horth C., Gros P (2014) Independent mutations at Arg181 and Arg274 of Vangl proteins that are associated with neural tube defects in humans decrease protein stability and impair membrane targeting. *Biochemistry* **53**:5356-5364 <https://doi.org/10.1021/bi500400g>
- 45 Tian T., et al. (2020) Rare copy number variations of planar cell polarity genes are associated with human neural tube defects. *Neurogenetics* **21**:217-225 <https://doi.org/10.1007/s10048-020-00613-6>
- 46 Lei Y. P., et al. (2010) VANGL2 mutations in human cranial neural-tube defects. *N Engl J Med* **362**:2232-2235 <https://doi.org/10.1056/NEJMc0910820>
- 47 Kibar Z., et al. (2011) Contribution of VANGL2 mutations to isolated neural tube defects. *Clin Genet* **80**:76-82 <https://doi.org/10.1111/j.1399-0004.2010.01515.x>
- 48 Aguiar-Pulido V., et al. (2021) Systems biology analysis of human genomes points to key pathways conferring spina bifida risk. *Proc Natl Acad Sci U S A* **118** <https://doi.org/10.1073/pnas.2106844118>
- 49 Karzbrun E., et al. (2021) Human neural tube morphogenesis in vitro by geometric constraints. *Nature* **599**:268-272 <https://doi.org/10.1038/s41586-021-04026-9>
- 50 Takla T. N., et al. (2023) A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects. *Cells* **12** <https://doi.org/10.3390/cells12131697>

- 51 Tidball A. M., et al. (2023) Deriving early single-rosette brain organoids from human pluripotent stem cells. *Stem Cell Reports* **18**:2498-2514 <https://doi.org/10.1016/j.stemcr.2023.10.020>
- 52 Mirdass C., Catala M., Bocel M., Nedelec S., Ribes V (2023) Stem cell-derived models of spinal neurulation. *Emerg Top Life Sci* **7**:423-437 <https://doi.org/10.1042/ETLS20230087>
- 53 Abdel Fattah A. R., Grebenyuk S., de Rooij L., Salmon I., Ranga A. (2023) Neuroepithelial organoid patterning is mediated by a neighborhood watch mechanism. *Cell Rep* **42** <https://doi.org/10.1016/j.celrep.2023.113334>
- 54 Krammer T., et al. (2024) Mouse neural tube organoids self-organize floorplate through BMP-mediated cluster competition. *Dev Cell* **59**:1940-1953.e1910 <https://doi.org/10.1016/j.devcel.2024.04.021>
- 55 Rabeling A., van der Hoven A., Andersen N., Goolam M (2024) Neural Tube Organoids: A Novel System to Study Developmental Timing. *Stem Cell Rev Rep* **20**:2045-2061 <https://doi.org/10.1007/s12015-024-10785-5>
- 56 Shi Y., Kirwan P., Livesey F. J (2012) Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat Protoc* **7**:1836-1846 <https://doi.org/10.1038/nprot.2012.116>
- 57 Gagliano O., et al. (2019) Microfluidic reprogramming to pluripotency of human somatic cells. *Nat Protoc* **14**:722-737 <https://doi.org/10.1038/s41596-018-0108-4>
- 58 Maniou E., et al. (2024) Quantifying mechanical forces during vertebrate morphogenesis. *Nat Mater* **23**:1575-1581 <https://doi.org/10.1038/s41563-024-01942-9>
- 59 Bluhmki T., et al. (2019) Differentiation of hiPS Cells into Definitive Endoderm for High-Throughput Screening. *Methods Mol Biol* **1994**:101-115 https://doi.org/10.1007/978-1-4939-9477-9_9
- 60 Zhang P. P., et al. (2024) Adapting the endoplasmic reticulum proteostasis rescues epilepsy-associated NMDA receptor variants. *Acta Pharmacol Sin* **45**:282-297 <https://doi.org/10.1038/s41401-023-01172-w>
- 61 Inoue Y., et al. (2016) Mechanical roles of apical constriction, cell elongation, and cell migration during neural tube formation in *Xenopus*. *Biomech Model Mechanobiol* **15**:1733-1746 <https://doi.org/10.1007/s10237-016-0794-1>
- 62 Schoenwolf G. C., Franks M. V (1984) Quantitative analyses of changes in cell shapes during bending of the avian neural plate. *Dev Biol* **105**:257-272 [https://doi.org/10.1016/0012-1606\(84\)90284-7](https://doi.org/10.1016/0012-1606(84)90284-7)
- 63 Matsuda M., Rozman J., Ostvar S., Kasza K. E., Sokol S. Y (2023) Mechanical control of neural plate folding by apical domain alteration. *Nat Commun* **14**:8475 <https://doi.org/10.1038/s41467-023-43973-x>
- 64 Campas O., Noordstra I., Yap A. S (2024) Adherens junctions as molecular regulators of emergent tissue mechanics. *Nat Rev Mol Cell Biol* **25**:252-269 <https://doi.org/10.1038/s41580-023-00688-7>
- 65 Ossipova O., Chuykin I., Chu C. W., Sokol S. Y (2015) Vangl2 cooperates with Rab11 and Myosin V to regulate apical constriction during vertebrate gastrulation. *Development* **142**:99-107 <https://doi.org/10.1242/dev.111161>
- 66 Humphries A. C., Narang S., Mlodzik M (2020) Mutations associated with human neural tube defects display disrupted planar cell polarity in *Drosophila*. *eLife* **9** <https://doi.org/10.7554/eLife.53532>
- 67 Kasioulis I., et al. (2022) A lateral protrusion latticework connects neuroepithelial cells and is regulated during neurogenesis. *J Cell Sci* **135** <https://doi.org/10.1242/jcs.259897>
- 68 Ito M., Okano H. J., Darnell R. B., Roeder R. G (2002) The TRAP100 component of the TRAP/Mediator complex is essential in broad transcriptional events and development. *EMBO J* **21**:3464-3475 <https://doi.org/10.1093/emboj/cdf348>
- 69 Hofacker I. L., Stadler P. F (2006) Memory efficient folding algorithms for circular RNA secondary structures. *Bioinformatics* **22**:1172-1176 <https://doi.org/10.1093/bioinformatics/btl023>
- 70 Rubio S., et al. (2024) Nuclear VANGL2 Inhibits Lactogenic Differentiation. *Cells* **13** <https://doi.org/10.3390/cells13030222>

- 71 Walton A., et al. (2024) A vertebrate Vangl2 translational variant required for planar cell polarity. *J Biol Chem* **300** <https://doi.org/10.1016/j.jbc.2024.106792>
- 72 How J. Y., Stephens R. K., Lim K. Y. B., Humbert P. O., Kvensakul M (2021) Structural basis of the human Scribble-Vangl2 association in health and disease. *Biochem J* **478**:1321-1332 <https://doi.org/10.1042/BCJ20200816>
- 73 Boeda B., et al. (2023) SCRIB controls apical contractility during epithelial differentiation. *J Cell Biol* **222** <https://doi.org/10.1083/jcb.202211113>
- 74 He B., Doubrovinski K., Polyakov O., Wieschaus E (2014) Apical constriction drives tissue-scale hydrodynamic flow to mediate cell elongation. *Nature* **508**:392-396 <https://doi.org/10.1038/nature13070>
- 75 Gelbart M. A., et al. (2012) Volume conservation principle involved in cell lengthening and nucleus movement during tissue morphogenesis. *Proc Natl Acad Sci U S A* **109**:19298-19303 <https://doi.org/10.1073/pnas.1205258109>
- 76 Martinez-Ara G., et al. (2022) Optogenetic control of apical constriction induces synthetic morphogenesis in mammalian tissues. *Nat Commun* **13**:5400 <https://doi.org/10.1038/s41467-022-33115-0>
- 77 de Goederen V., Vetter R., McDole K., Iber D (2022) Hinge point emergence in mammalian spinal neurulation. *Proc Natl Acad Sci U S A* **119**:e2117075119 <https://doi.org/10.1073/pnas.2117075119>
- 78 Ybot-Gonzalez P., Cogram P., Gerrelli D., Copp A. J (2002) Sonic hedgehog and the molecular regulation of mouse neural tube closure. *Development* **129**:2507-2517 <https://doi.org/10.1242/dev.129.10.2507>
- 79 Grego-Bessa J., et al. (2016) The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. *eLife* **5**:e12034 <https://doi.org/10.7554/eLife.12034>
- 80 Jacobson A. G., Tam P. P (1982) Cephalic neurulation in the mouse embryo analyzed by SEM and morphometry. *Anat Rec* **203**:375-396 <https://doi.org/10.1002/ar.1092030308>
- 81 De La O J., Okeke C., Galea G. L., Martin A. C (2025) An actomyosin-mediated mechanical mechanism for brain neural tube elevation. *bioRxiv* <https://doi.org/10.1101/2025.05.15.654327>
- 82 Brooks E. R., et al. (2025) A single-cell atlas of spatial and temporal gene expression in the mouse cranial neural plate. *eLife* **13** <https://doi.org/10.7554/eLife.102819>
- 83 Ohmura T., Shioi G., Hirano M., Aizawa S (2012) Neural tube defects by NUA1 and NUA2 double mutation. *Dev Dyn* **241**:1350-1364 <https://doi.org/10.1002/dvdy.23816>
- 84 Grego-Bessa J., Hildebrand J., Anderson K. V (2015) Morphogenesis of the mouse neural plate depends on distinct roles of cofilin 1 in apical and basal epithelial domains. *Development* **142**:1305-1314 <https://doi.org/10.1242/dev.115493>
- 85 Ito M., Yuan C. X., Okano H. J., Darnell R. B., Roeder R. G (2000) Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. *Mol Cell* **5**:683-693 [https://doi.org/10.1016/s1097-2765\(00\)80247-6](https://doi.org/10.1016/s1097-2765(00)80247-6)
- 86 Ramasamy S., et al. (2023) The Mediator complex regulates enhancer-promoter interactions. *Nat Struct Mol Biol* **30**:991-1000 <https://doi.org/10.1038/s41594-023-01027-2>
- 87 Ha Y. J., et al. (2025) The contribution of de novo coding mutations to meningocele. *Nature* <https://doi.org/10.1038/s41586-025-08676-x>
- 88 Rocha P. P., Scholze M., Bleiss W., Schrewe H (2010) Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. *Development* **137**:2723-2731 <https://doi.org/10.1242/dev.053660>
- 89 Haque F., Honjo T., Begum N. A (2022) XLID syndrome gene Med12 promotes Ig isotype switching through chromatin modification and enhancer RNA regulation. *Sci Adv* **8**:eadd1466 <https://doi.org/10.1126/sciadv.add1466>

- 90 Hamada N., Iwamoto I., Nishikawa M., Nagata K. I (2021) Expression Analyses of Mediator Complex Subunit 13-Like: A Responsible Gene for Neurodevelopmental Disorders during Mouse Brain Development. *Dev Neurosci* **43**:43-52 <https://doi.org/10.1159/000515188>
- 91 Zhu W., et al. (2015) Mediator Med23 deficiency enhances neural differentiation of murine embryonic stem cells through modulating BMP signaling. *Development* **142**:465-476 <https://doi.org/10.1242/dev.112946>
- 92 Leung K. Y., De Castro S. C., Savery D., Copp A. J., Greene N. D (2013) Nucleotide precursors prevent folic acid-resistant neural tube defects in the mouse. *Brain* **136**:2836-2841 <https://doi.org/10.1093/brain/awt209>
- 93 Wu Y., Peng S., Finnell R. H., Zheng Y (2021) Organoids as a new model system to study neural tube defects. *FASEB J* **35**:e21545 <https://doi.org/10.1096/fj.202002348R>
- 94 Li H., Zhang J., Niswander L (2025) Human organoids potentially boost research into environmental factors of neural tube defects. *Reprod Toxicol* **135**:108936 <https://doi.org/10.1016/j.reprotox.2025.108936>
- 95 Huang R. E., et al. (2025) Arrayed single-gene perturbations identify drivers of human anterior neural tube closure. *bioRxiv* <https://doi.org/10.1101/2025.07.21.665862>
- 96 Lee J. H., et al. (2022) Production of human spinal-cord organoids recapitulating neural-tube morphogenesis. *Nat Biomed Eng* **6**:435-448 <https://doi.org/10.1038/s41551-022-00868-4>
- 97 Biancotti J. C., et al. (2025) Spinal Cord Organoids from Human Amniotic Fluid iPSC Recapitulate the Diversity of Cell Phenotypes During Fetal Neural Tube Morphogenesis. *Mol Neurobiol* **62**:10954-10969 <https://doi.org/10.1007/s12035-025-04944-z>
- 98 Sahakyan V., et al. (2018) Folic Acid Exposure Rescues Spina Bifida Aperta Phenotypes in Human Induced Pluripotent Stem Cell Model. *Sci Rep* **8**:2942 <https://doi.org/10.1038/s41598-018-21103-8>
- 99 Strano A., Tuck E., Stubbs V. E., Livesey F. J (2020) Variable Outcomes in Neural Differentiation of Human PSCs Arise from Intrinsic Differences in Developmental Signaling Pathways. *Cell Rep* **31**:107732 <https://doi.org/10.1016/j.celrep.2020.107732>
- 100 Fietz S. A., Namba T., Kirsten H., Huttner W. B., Lachmann R (2020) Signs of Reduced Basal Progenitor Levels and Cortical Neurogenesis in Human Fetuses with Open Spina Bifida at 11-15 Weeks of Gestation. *J Neurosci* **40**:1766-1777 <https://doi.org/10.1523/JNEUROSCI.0192-19.2019>
- 101 Clark M., et al. (2025) Chiari II brain malformation is secondary to open spina bifida. *bioRxiv* <https://doi.org/10.1101/2025.01.06.631442>
- 102 Cheng X., et al. (2025) Trends of neural tube defects in urban China and effects of socio-demographic factors, 2013-2022: a descriptive analysis. *BMJ Public Health* **3**:e001489 <https://doi.org/10.1136/bmjph-2024-001489>
- 103 Sugai K., Nakamura M., Okano H., Nagoshi N (2025) Stem cell therapies for spinal cord injury in humans: A review of recent clinical research. *Brain Spine* **5**:104207 <https://doi.org/10.1016/j.bas.2025.104207>
- 104 Beers J., et al. (2012) Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. *Nat Protoc* **7**:2029-2040 <https://doi.org/10.1038/nprot.2012.130>
- 105 Yin H., Copley C. O., Goodrich L. V., Deans M. R (2012) Comparison of phenotypes between different vangl2 mutants demonstrates dominant effects of the Looptail mutation during hair cell development. *PLoS One* **7**:e31988 <https://doi.org/10.1371/journal.pone.0031988>
- 106 Maniou E., et al. (2021) Hindbrain neuropore tissue geometry determines asymmetric cell-mediated closure dynamics in mouse embryos. *Proc Natl Acad Sci U S A* **118** <https://doi.org/10.1073/pnas.2023163118>
- 107 Tseng Q., et al. (2012) Spatial organization of the extracellular matrix regulates cell-cell junction positioning. *Proc Natl Acad Sci U S A* **109**:1506-1511 <https://doi.org/10.1073/pnas.1106377109>

- 108 Thompson E. M., Patel V., Rajeeve V., Cutillas P. R., Stoker A. W (2022) The cytotoxic action of BCI is not dependent on its stated DUSP1 or DUSP6 targets in neuroblastoma cells. *FEBS Open Bio* 12:1388-1405 <https://doi.org/10.1002/2211-5463.13418>
- 109 Chen S., et al. (2024) A genomic mutational constraint map using variation in 76,156 human genomes. *Nature* 625:92-100 <https://doi.org/10.1038/s41586-023-06045-0>

Peer reviews

Reviewer #1 (Public review):

Summary:

In this manuscript, Ampartzidis et al. report the establishment of an iPSC-derived neuroepithelial model to examine how mutations from spina bifida patients disrupt fundamental cellular properties that underlie neural tube closure. The authors utilize an adherent neural induction protocol that relies on dual SMAD inhibition to differentiate three previously established iPSC lines with different origins and reprogramming methods. The analysis is comprehensive and outstanding, demonstrating reproducible differentiation, apical-basal elongation, and apical constriction over an 8-day period among the 3 lines. In inhibitor studies, it is shown that apical constriction is dependent on ROCK and generates tension, which can be measured using an annular laser ablation assay. Since this pathway is dependent on PCP signaling, which is also implicated in neural tube defects, the authors investigated whether VANGL2 is required by generating 2 lines with a pathogenic patient-derived sequence variant. Both lines showed reduced apical constriction and reduced tension in the laser ablation assays. The authors then established lines obtained from amniocentesis, including 2 control and 2 spina bifida patient-derived lines. These remarkably exhibited different defects. One line showed defects in apical-basal elongation, while the other showed defects in neural differentiation. Both lines were sequenced to identify candidate variants in genes implicated in NTDs. While no smoking gun was found in the line that disrupts neural differentiation (as is often the case with NTDs), compound heterozygous MED24 variants were found in the patient whose cells were defective in apical-basal elongation. Since MED24 has been linked to this phenotype, this finding is especially significant.

Some details are missing regarding the method to evaluate the rigor and reproducibility of the study.

Major Comments:

It is mentioned throughout the manuscript that 3 plates were evaluated per line. I believe these are independently differentiated plates. This detail is critical concerning rigor and reproducibility. This should be clearly stated in the Methods section and in the first description of the experimental system in the Results section for Figure 1.

For the patient-specific lines - how many lines were derived per patient?

Was the Vangl2 variant introduced by prime editing? Base editing? The details of the methods are sparse.

Significance:

This paper is significant not only for verifying the cell behaviors necessary for neural tube closure in a human iPSC model, but also for establishing a robust assay for the functional testing of NTD-associated sequence variants. This will not only demonstrate that sequence variants result in loss of function but also determine which cellular behaviors are disrupted.

<https://doi.org/10.7554/eLife.110388.1.sa3>

Reviewer #2 (Public review):

Summary:

The authors' work focuses on studying cell morphological changes during differentiation of hPSCs into neural progenitors in a 2D monolayer setting. The authors use genetic mutations in *VANGL2* and patient-derived iPSCs to show that (1) human phenotypes can be captured in the 2D differentiation assay, and (2) *VANGL2* in humans is required for neural contraction, which is consistent with previous studies in animal models. The results are solid and convincing, the data are quantitative, and the manuscript is well written. The 2D model they present successfully addresses the questions posed in the manuscript. However, the broad impact of the model may be limited, as it does not contain NNE cells and does not exhibit tissue folding or tube closure, as seen in neural tube formation. Patient-derived lines are derived from amniotic fluid cells, and the experiments are performed before birth, which I find to be a remarkable achievement, showing the future of precision medicine.

Major comments:

- (1) Figure 1. The authors use F-actin to segment cell areas. Perhaps this could be done more accurately with ZO-1, as F-actin cables can cross the surface of a single cell. In any case, the authors need to show a measure of segmentation precision: segmented image vs. raw image plus a nuclear marker (DAPI, H2B-GFP), so we can check that the number of segmented cells matches the number of nuclei.
- (2) Lines 156-166. The authors claim that changes in gene expression precede morphological changes. I am not convinced this is supported by their data. Fig. 1g (epithelial thickness) and Fig. 1k (PAX6 expression) seem to have similar dynamics. The authors can perform a cross-correlation between the two plots to see which Δt gives maximum correlation. If $\Delta t < 0$, then it would suggest that gene expression precedes morphology, as they claim. Fig. 1j shows that *NANOG* drops before the morphological changes, but loss of *NANOG* is not specific to neural differentiation and therefore should not be related to the observed morphological changes.
- (3) Figure 2d. The laser ablation experiment in the presence of ROCK inhibitor is clear, as I can easily see the cell outlines before and after the experiment. In the absence of ROCK inhibitor, the cell edges are blurry, and I am not convinced the outline that the authors drew is really the cell boundary. Perhaps the authors can try to ablate a larger cell patch so that the change in area is more defined.
- (4) Figure 2d. Do the cells become thicker after recoil?
- (5) Figure 3. The authors mention their previous study in which they show that *Vangl2* is not cell-autonomously required for neural closure. It will be interesting to study whether this also the case in the present human model by using mosaic cultures.
- (6) Lines 403-415. The authors report poor neural induction and neuronal differentiation in GOSB2. As far as I understand, this phenotype does not represent the *in vivo* situation. Thus, it is not clear to what extent the *in vitro* 2D model describes the human patient.
- (7) The experimental feat to derive cell lines from amniotic fluid and to perform experiments before birth is, in my view, heroic. However, I do not feel I learned much from the *in vitro* assays. There are many genetic changes that may cause the *in vivo* phenotype in the patient. The authors focus on *MED24*, but there is not enough convincing evidence that this is the key gene. I would like to suggest overexpression of *MED24* as a rescue experiment, but I am not sure this is a single-gene phenotype. In addition, the fact that one patient line does not differentiate properly leads me to think that the patient lines do not strengthen the manuscript, and that perhaps additional clean mutations might contribute more.

Significance:

This study establishes a quantitative, reproducible 2D human iPSC-to-neural-progenitor platform for analyzing cell-shape dynamics during differentiation. Using VANGL2 mutations and patient-derived iPSCs, the work shows that (1) human phenotypes can be captured in a 2D differentiation assay and (2) VANGL2 is required for neural contraction (apical constriction), consistent with animal studies. The results are solid, the data are quantitative, and the manuscript is well written. Although the planar system lacks non-neural ectoderm and does not exhibit tissue folding or tube closure, it provides a tractable baseline for mechanistic dissection and genotype-phenotype mapping. The derivation of patient lines from amniotic fluid and execution of experiments before birth is a remarkable demonstration that points toward precision-medicine applications, while motivating rescue strategies and additional clean genetic models. However, overall, I did not learn anything substantively new from this manuscript; the conclusions largely corroborate prior observations rather than extend them. In addition, the model was unsuccessful in one of the two patient-derived lines, which limits generalizability and weakens claims of patient-specific predictive value.

<https://doi.org/10.7554/eLife.110388.1.sa2>

Reviewer #3 (Public review):

Summary:

This manuscript by Ampartzidis et al., significantly extends the human induced pluripotent stem cell system originally characterized by the same group as a tool for examining cellular remodeling during differentiation stages consistent with those of human neural tube closure (Ampartzidis et al., 2023). Given that there are no direct ways to analyze cellular activity in human neural tube closure in vivo, this model represents an important platform for investigating neural tube defects which are a common and deleterious human developmental disease. Here, the authors carefully test whether this system is robust and reproducible when using hiPSC cells from different donors and pluripotency induction methods and find that despite all these variables the cellular remodeling programs that occur during early neural differentiation are statistically equivalent, suggesting that this system is a useful experimental substrate. Additionally, the carefully selected donor populations suggest these aspects of human neural tube closure are likely to be robust to sexual dimorphism and to reasonable levels of human genetic background variation, though more fully testing that proposition would require significant effort and be beyond the scope of the current work. Subsequent to this careful characterization, the authors next tested whether this system could be used to derive specific insights into cell remodeling during early neural differentiation. First, they used a reverse genetics approach to knock in a human point mutation in the critical regulator of planar cell polarity and apical constriction, *Vangl2*. Despite being identified in a patient, this R353C variant has not been directly functionally tested in a human system. The authors find that this variant, despite showing normal expression and phospho-regulation, leads to defects consistent with a failure in apical constriction, a key cell behavior required to drive curvature change during cranial closure. Finally, the authors test the utility of their hiPSC platform to understand human patient-specific defects by differentiating cells derived from two clinical spina bifida patients. The authors identify that one of these patients is likely to have a significant defect in fully establishing early proneural identity as well as defects in apicobasal thickening. While early remodeling occurs normally in the other patient, the authors observe significant defects in later neuronal induction and maturation. In addition, using whole exome sequencing the authors identify candidate variant loci that could underly these defects.

Major comments:

(1) One of my few concerns with this work is that the relative constriction of the apical surface with respect to the basal surface is not directly quantified for any of the experiments. This worry is slightly compounded by the 3D reconstructions Figure 1h, and the observation that overall cell volume is reduced and cell height increased simultaneously to area loss. Additionally, the net impact of apical constriction in tissues in vivo is to create local or global curvature change, but all the images in the paper suggest that the differentiated neural tissues are an uncurved monolayer even missing local buckles. I understand that these cells are grown on flat adherent surfaces limiting global curvature change, but is there evidence of localized buckling in the monolayer? While I believe-along with the authors-that their phenotypes are likely failures in apical constriction, I think they should work to strengthen this conclusion. I think the easiest way (and hopefully using data they already have) would be to directly compare apical area to basal area on a cell wise basis for some number of cells. Given the heterogeneity of cells, perhaps 30-50 cells per condition/line/mutant would be good? I am open to other approaches; this just seems like it may not require additional experiments.

(2) Another slight experimental concern I have regards the difference in laser ablation experiments detailed in Figure 3h-i from those of Figure 2d-e. It seems like WT recoil values in 3h-I are more variable and of a lower average than the earlier experiments and given that it appears significance is reached mainly by impact of the lower values, can the authors explain if this variability is expected to be due to heterogeneity in the tissue, i.e. some areas have higher local tension? If so, would that correspond with more local apical constriction?

Significance:

Overall, I am enthusiastic about this work and believe it represents a significant step forward in the effort to establish precision medicine approaches for diagnoses of the patient-specific causative cellular defects underlying human neural tube closure defects. This work systematizes an important and novel tool to examine the cellular basis of neural tube defects. While other hiPSC models of neural tube closure capture some tissue level dynamics, which this model does not, they require complex microfluidic approaches and have limited accessibility to direct imaging of cell remodeling. Comparatively, the relative simplicity of the reported model and the work demonstrating its tractability as a patient-specific and reverse genetic platform make it unique and attractive. This work will be of interest to a broad cross section of basic scientists interested in the cellular basis of tissue remodeling and/or the early events of nervous system development as well as clinical scientists interested in modeling the consequences of patient specific human genetic deficits identified in neural tube defect pregnancies.

<https://doi.org/10.7554/eLife.110388.1.sa1>

Author response:

General Statements

In this manuscript we characterize an exquisitely reproducible model of iPSC differentiation into neuroepithelial cells, use it to mechanistically study cell shape changes and planar cell polarity signaling activation during this transition, then apply it to identify patient-specific cell deficiencies in both forward and reverse genetic screens as a power tool for patient-stratification in personalized medicine. To our knowledge, we provide the first evidence of a human pathogenic mutation directly impairing apical constriction: an evolutionarily conserved behavior of epithelial cells which is the subject of intense research.

We are very pleased with the balanced and rigorous reviews generated through Review Commons, which we have already used to improve our manuscript. Reviewer 1 highlights

that our study “is significant not only for verifying the cell behaviors necessary for neural tube closure in a human iPSC model, but also for establishing a robust assay for the functional testing of NTD-associated sequence variants.” Reviewer 2 agrees that “results are solid and convincing, the data are quantitative, and the manuscript is well written”, and that our “derivation of patient lines from amniotic fluid and execution of experiments before birth is a remarkable demonstration that points toward precision-medicine applications, while motivating rescue strategies and additional clean genetic models.” Reviewer 3 is “enthusiastic about this work and believe it represents a significant step forward in the effort to establish precision medicine approaches for diagnoses of the patient-specific causative cellular defects underlying human neural tube closure defects.”

Below, we have replied to each of the reviewers’ comments.

Description of the planned revisions

R2.2. Lines 156-166. The authors claim that changes in gene expression precede morphological changes. I am not convinced this is supported by their data. Fig. 1g (epithelial thickness) and Fig. 1k (PAX6 expression) seem to have similar dynamics. The authors can perform a cross-correlation between the two plots to see which Δt gives maximum correlation. If $\Delta t < 0$, then it would suggest that gene expression precedes morphology, as they claim. Fig. 1j shows that NANOG drops before the morphological changes, but loss of NANOG is not specific to neural differentiation and therefore should not be related to the observed morphological changes.

We are happy to do this analysis fully in revision. Our initial analysis performing crosscorrelation between apical area and CDH2 protein in one line shows the highest crosscorrelation at $\Delta t = -1$, suggesting neuroepithelial CDH2 increases before apical area decreases. In contrast, the same analysis comparing apical area versus PAX6 shows $\Delta t = 0$, suggesting concurrence. This analysis will be expanded to include the other markers we quantified and the manuscript text amended accordingly. We are keen to undertake additional experiments to test whether these cells swap their key cadherins – CDH1 and CDH2 - before they begin to undergo morphological changes (see the response to Reviewer 3’s minor comment 1 immediately below).

R3.1(Minor) There seems to be a critical window at day 5 of the differentiation protocol, both in terms of cell morphology and the marker panel presented in Figure 1i. Do the authors have any data spanning the hours from day 5 to 6? If not, I don't think they need to generate any, but do I think this is a very interesting window worthy of further discussion for a couple of reasons. First, several studies of mouse neural tube closure have shown that various aspects of cell remodeling are temporally separable. For example, between Grego-Bessa et al 2016 and Brooks et al 2020 we can infer that apicobasal elongation rapidly increases starting at E8.5, whereas apical surface area reduction and constriction are apparent somewhat earlier at E8.0. I think it would be interesting to see if this separability is conserved in humans. Second, is there a sense of how the temporal correlation between the pluripotent and early neural fate marker data presented here corroborate or contradict the emerging set of temporally resolved RNA seq data sets of mouse development at equivalent early neural stages?

Cell shape analysis between days 5 and 6 has now been added (see the response to point 2.1 below). As the reviewer predicted, this is a transition point when apical area begins to decrease and apicobasal elongation begins to increase.

We also thank the reviewer for this prompt to more closely compare our data to the previous mouse publications, which we have added to the discussion. The Grego-Bessa 2016 paper appears to show an increase in thickness between E7.75 and E8.5, but these are not statistically compared. Previous studies showed rapid apicobasal elongation during the

period of neural fold elevation, when neuroepithelial cells apically constrict. This has now been added to the discussion:

Discussion: “In mice, neuroepithelial apicobasal thickness is spatially-patterned, with shorter cells at the midline under the influence of SHH signalling[14,77,78]. Apicobasal thickness of the cranial neural folds increases from ~25 μm at E7.75 to ~50 μm at E8.5[79]: closely paralleling the elongation between days 2 and 8 of differentiation in our protocol. The rate of thickening is non-uniform, with the greatest increase occurring during elevation of the neural folds[80], paralleled in our model by the rapid increase in thickness between days 4-6 as apical areas decrease. Elevation requires neuroepithelial apical constriction and these cells’ apical area also decreases between E7.75 and E8.5 in mice[79], but we and others have recently shown that this reduction is both region and sex-specific[14,81]. Specifically, apical constriction occurs in the lateral (future dorsal) neuroepithelium: this corresponds with the identity of the cells generated by the dual SMAD inhibition model we use[56]. More recently, Brooks et al[82] showed that the rapid reduction in apical area from E8-E8.5 is associated with cadherin switching from CDH1 (E-cadherin) to CDH2 (N-cadherin). This is also directly paralleled in our human system, which shows low-level co-expression of CDH1 and CDH2 at day 4 of differentiation, immediately before apical area shrinks and apicobasal thickness increases.”

Prompted by the *in vivo* data in Brooks et al (2025)[82], we are keen to further explore the timing of CDH1/CDH2 switching versus apical constriction with new experimental data in revisions.

R3.2(Minor) 2) Can the authors elaborate a bit more on what is known regarding apicobasal thickening and pseudo-stratification and how their work fits into the current understanding in the discussion? This is a very interesting and less well studied mechanism critical to closure, which their model is well suited to directly address. I am thinking mainly of the Grego-Bessa et al., 2016 work on PTEN, though interestingly the work of Ohmura et al., 2012 on the NUA kinases also shows reduced tissue thickening (and apical constriction) and I am sure I have missed others. Given that the authors identify MED24 as a likely candidate for the lack of apicobasal thickening in one of their patient derived lines, is there any evidence that it interacts with any of the known players?

We have now added further discussion on the mechanisms by which the neuroepithelium undergoes apicobasal elongation. Nuclear compaction is likely to be necessary to allow pseudostratification and apicobasal elongation. The reviewer’s comment has led us to realise that diminished chromatin compaction is a potential outcome of MED24 down-regulation in our GOSB2 patient-derived line. Figure 4D suggests the nuclei of our MED24 deficient patient-derived line are less compacted than control equivalents and we propose to quantify nuclear volume in more detail to explore this possibility.


Additionally, we have already expanded our discussion as suggested by the reviewer:

Discussion: “Mechanistic separability of apical constriction and apicobasal elongation is consistent with biomechanical modelling of *Xenopus* neural tube closure showing that both are independently required for tissue bending[61]. Nonetheless, neuroepithelial apical constriction and apicobasal elongation are co-regulated in mouse models: for example, deletion of *Nuak1/2*[83], *Cfl1*[84], and *Pten*[79] all produce shorter neuroepithelium with larger apical areas. Neuroepithelial cells of the GOSB2 line described here, which has partial loss of MED24, similarly produces a thinner neuroepithelium with larger apical areas. Although apical areas were not analysed in mouse models of *Med24* deletion, these embryos also have shorter and non-pseudostratified neuroepithelium.

Our GOSB2 line – which retains readily detectable MED24 protein – is clearly less severe than the mouse global knockout, and the clinical features of the patient from which this line was derived are milder than the phenotype of Med24 knockout embryos[68]. Mouse embryos lacking one of *Med24*'s interaction partners in the mediator complex, *Med1*, also have thinner neuroepithelium and diminished neuronal differentiation but successfully close their neural tube[85]. As general regulators of polymerase activity, MED proteins have the potential to alter the timing or level of expression of many other genes, including those already known to influence pseudostratification or apicobasal elongation. MED depletion also causes redistribution of cohesion complexes[86] which may impact chromatin compaction, reducing nuclear volume during differentiation.”

R3.3(Minor) 3) Is there any indication that Vangl2 is weakly or locally planar polarized in this system? Figure 2F seems to suggest not, but [Supplementary Figure 5](#) does show at least more supracellular cable like structures that may have some polarity. I ask because polarization seems to be one of the properties that differs along the anteroposterior axis of the neural plate, and I wonder if this offers some insight into the position along the axis that this system most closely models?

VANGL2 does not appear to be planar polarised in this system. This is similar to the mouse spinal neuroepithelium, in which apical VANGL2 is homogenous but F-actin is planar polarised (Galea et al Disease Models and Mechanisms 2018). We do observe local supracellular cablelike enrichments of F-actin in the apical surface of iPSC-derived neuroepithelial cells:



Author response image 1. Preliminary identification of apical supracellular cables suggestive of local polarity. Top: F-actin staining shown in inverted grey LUT highlighting enrichment along directionally-polarised cell borders (blue arrows). Bottom: Staining orientation (blue ~ X axis, red ~ Y axis) based on OrientationJ analysis illustrating localised organisation of F-actin enrichment.

We propose to compare the length of F-actin cables and coherency of their orientation at the start and end of neuroepithelial differentiation, and in wild-type versus *VANGL2* mutant epithelia.

Description of the revisions that have already been incorporated in the transferred manuscript

Reviewer #1:

Major points

(1) It is mentioned throughout the manuscript that 3 plates were evaluated per line. I believe these are independently differentiated plates. This detail is critical concerning rigor and reproducibility. This should be clearly stated in the Methods section and in the first description of the experimental system in the Results section for Figure 1.

These experimental details have now been clarified. Unless otherwise stated, all findings were confirmed in three independently differentiated plates from the same line or at least one differentiation from each of three lines.

Methods: Unless otherwise stated, for each iPSC line three independently differentiated plates were generated and analysed, with each plate representing a separate differentiation experiment performed on different days.

(2) For the patient-specific lines - how many lines were derived per patient?

This has now been clarified in the methods. Microfluidic reprogramming of a small number of amniocytes produces one line per patient representing a pool of clones. Subcloning from individual cells would not be possible within the timeframe of a pregnancy.


Methods: For patient-specific iPSC lines, one independent iPSC line was obtained per patient following microfluidic mRNA reprogramming.

(3) Was the *Vangl2* variant introduced by prime editing? Base editing? The details of the methods are sparse.

We have now expanded these details:

Methods: "VANGL2 knock-in lines were generated using CRISPR-Cas9 homology directed repair editing by Synthego (SO-9291367-1). The guide sequence was AUGAGCGAAGGGUGCGCAAG and the donor sequence was CAATGAGTACTACTATGAGGAGGCTGAGCATGAGCGAAGGGTGTGCAAGAGGAGGGCCAGGTGGGTCCCTGGG.

Sequence modification was confirmed by Sanger sequencing before delivery of the modified clones, and Sanger sequencing was repeated after expansion of the lines (Supplementary Figure 5) as well as SNP arrays (Illumina iScan, not shown) confirming genomic stability."



Author response image 2. Snapshot of Illumina iScan SNP array showing absence of chromosomal duplications or deletions in the CRISPR-modified *VANGL2*-knockin lines or their congenic control.

(4) Suggested text changes.

Some additional suggestions for improvement.

The abstract could be more clearly written to effectively convey the study's importance. Here are some suggestions

Line 26: Insert "apicobasal" before "elongation" - the way it is written, I initially interpreted it as anterior-posterior elongation.

Line 29: Please specify that the lines refer to 3 different established parent iPSC lines with distinct origins and established using different reprogramming methods, plus 2 control patient-derived lines. - The reproducibility of the cell behaviors is impressive, but this is not captured in the abstract.

Line 32: add that this mutation was introduced by CRISPR-Cas9 base/prime editing.

The last sentence of the abstract states that the study only links apical constriction to human NTDs, but also reveals that neural differentiation and apical-basal elongation were found. The introduction could also use some editing.

Line 71: insert "that pulls actin filaments together" after "power strokes" Line 73: "apically localized," do you mean "mediolaterally" or "radially"?

Line 75: Can you specify that PCP components promote "mediolaterally orientated" apical constriction Lines 127: Specify that NE functions include apical basal elongation and neurodifferentiation are disrupted in patient-derived models

All have now been corrected.

Reviewer #2:

Major comments:

(1) Figure 1. The authors use F-actin to segment cell areas. Perhaps this could be done more accurately with ZO-1, as F-actin cables can cross the surface of a single cell. In any case, the authors need to show a measure of segmentation precision: segmented image vs. raw image plus a nuclear marker (DAPI, H2B-GFP), so we can check that the number of segmented cells matches the number of nuclei.

We used ZO-1 to quantify apical areas of the VANGL2-konckin lines in Figure 3. Segmentation of neuroepithelial apical areas based on F-actin staining is commonplace in the field (e.g. in the Brooks et al 2022 paper cited by another reviewer), and is generally robust because the cell junctions are much brighter than any apical fibres not associated with the apical cortex. However, we accept that at earlier stages of differentiation there may be more apical fibres when cells are cuboidal. We have therefore repeated our analysis of apical area using ZO-1 staining as suggested, analysing a more temporally-detailed time course in one iPSC line. This new analysis confirms our finding of lack of apical area change between days 2-4 of differentiation, then progressive reduction of apical area between days 4-8, further validating our system. Including nuclear images is not helpful because of the high nuclear index of pseudostratified epithelia (e.g. see [Supplementary Figure 7](#)) which means that nuclei overlap along the apicobasal axis. Individual nuclei cannot be related to their apical surface in projected images.

(3) Figure 2d. The laser ablation experiment in the presence of ROCK inhibitor is clear, as I can easily see the cell outlines before and after the experiment. In the absence of ROCK inhibitor, the cell edges are blurry, and I am not convinced the outline that the authors drew is really the cell boundary. Perhaps the authors can try to ablate a larger cell patch so that the change in area is more defined.

The outlines on these images are not intended to show cell boundaries, but rather link landmarks visible at both timepoints to calculate cluster (not cell) change in area. This is as previously shown in Galea et al Nat Commun 2021 and Butler et al J Cell Sci 2019. We have now amended the visualisation of retraction to make representation of differences between conditions more intuitive.

(4) Figure 2d. Do the cells become thicker after recoil?

This is unlikely because the ablated surface remains in the focal plane. Unfortunately, we are unable to image perpendicularly to the direction of ablation to test whether their apical surface moves in Z even by a very small amount. This has now been clarified in the results:

Results: “The ablated surface remained within the focal plane after ablation, indicating minimal movement along the apical-basal axis.”

(6) Lines 403-415. The authors report poor neural induction and neuronal differentiation in GOSB2. As far as I understand, this phenotype does not represent the *in vivo* situation. Thus, it is not clear to what extent the *in vitro* 2D model describes the human patient.

The GOSB2 iPSC line we describe does represent the *in vivo* situation in *Med24* knockout mouse embryos, but is clearly less severe because we are still able to detect MED24 protein expressed in this line. We do not have detailed clinical data of the patient from which this line was obtained to determine whether their neurological development is normal. However, it is well established that some individuals who have spina bifida also have abnormalities in supratentorial brain development. It is therefore likely that abnormalities in neuron differentiation/maturation are concomitant with spina bifida. Our findings in the GOSB2 line complement earlier studies which also identified deficiencies in the ability of patient-derived lines to form neurons, but were unable to functionally assess neuroepithelial cell behaviours we studied. This has now been clarified in the discussion:

Discussion: “Neuroepithelial cells of the GOSB2 line described here, which has partial loss of MED24, similarly produces a thinner neuroepithelium with larger apical areas. Although apical areas were not analysed in mouse models of *Med24* deletion, these embryos also have shorter and non-pseudostratified neuroepithelium.

Our GOSB2 line – which retains readily detectable MED24 protein – is clearly less severe than the mouse global knockout, and the clinical features of the patient from which this line was derived are milder than the phenotype of *Med24* knockout embryos[68].

Mouse embryos lacking one of *Med24*’s interaction partners in the mediator complex, *Med1*, also have thinner neuroepithelium and diminished neuronal differentiation but successfully close their neural tube[85].”

(7) The experimental feat to derive cell lines from amniotic fluid and to perform experiments before birth is, in my view, heroic. However, I do not feel I learned much from the *in vitro* assays. There are many genetic changes that may cause the *in vivo* phenotype in the patient. The authors focus on MED24, but there is not enough convincing evidence that this is the key gene. I would like to suggest overexpression of MED24 as a rescue experiment, but I am not sure this is a single-gene phenotype. In addition, the fact that one patient line does not differentiate properly leads me to think that the patient lines do not strengthen the manuscript, and that perhaps additional clean mutations might contribute more.

We appreciate the reviewer’s praise of our personalised medicine approach and fully agree that neural tube defects are rarely monogenic. The patient lines we studied were not intended to provide mechanistic insight, but rather to demonstrate the future applicability of our approach to patient care. Our vision is that every patient referred for fetal surgery of spina bifida will have amniocytes (collected as part of routine cystocentesis required before surgery) reprogrammed and differentiated into neuroepithelial cells, then neural progenitors, to help stratify their postnatal care. One could also picture these cells becoming an autologous source for future cellbased therapies if they pass our reproducible analysis pipeline as functional quality control. This has now been clarified in the discussion:

Discussion: “The multi-genic nature of neural tube defect susceptibility, compounded by uncontrolled environmental risk factors (including maternal age and parity[102]), mean that patient-derived iPSC models are unlikely to provide mechanistic insight. They do provide personalised disease models which we anticipate will enable functional validation of genetic diagnoses for patients and their parents’ recurrence risk in future pregnancies, and may

eventually stratify patients' postnatal care. We also envision this model will enable quality control of patient-derived cells intended for future autologous cell replacement therapies, as is being developed in post-natal spinal cord injury[103]. Thus, the highly reproducible modelling platform we evaluate – which is robust to differences in iPSC reprogramming method, sex and ethnicity – represents a valuable tool for future mechanistic insights and personalised disease modelling applications.”

Significance:

In addition, the model was unsuccessful in one of the two patient-derived lines, which limits generalizability and weakens claims of patient-specific predictive value.

We disagree with the reviewer that “the model was unsuccessful in one of the two patient-derived lines”. The GOSB1 line demonstrated deficiency of neuron differentiation independently of neuroepithelial biomechanical function, whereas the GOSB2 line showed earlier failure of neuroepithelial function. We also do not, at this stage, make patient-specific predictive claims: this will require longer-term matching of cell model findings with patient phenotypes over the next 5-10 years.

Reviewer #3:

Major comments

(1) One of my few concerns with this work is that the relative constriction of the apical surface with respect to the basal surface is not directly quantified for any of the experiments. This worry is slightly compounded by the 3D reconstructions Figure 1h, and the observation that overall cell volume is reduced and cell height increased simultaneously to area loss. Additionally, the net impact of apical constriction in tissues in vivo is to create local or global curvature change, but all the images in the paper suggest that the differentiated neural tissues are an uncurved monolayer even missing local buckles. I understand that these cells are grown on flat adherent surfaces limiting global curvature change, but is there evidence of localized buckling in the monolayer? While I believe-along with the authors-that their phenotypes are likely failures in apical constriction, I think they should work to strengthen this conclusion. I think the easiest way (and hopefully using data they already have) would be to directly compare apical area to basal area on a cell wise basis for some number of cells. Given the heterogeneity of cells, perhaps 30-50 cells per condition/line/mutant would be good? I am open to other approaches; this just seems like it may not require additional experiments.


As the reviewer observes, our cultures cannot bend because they are adhered on a rigid surface. The apical and basal lengths of the cultures will therefore necessarily be roughly equal in length. Some inwards bending of the epithelium is expected at the edges of the dish, but these cannot be imaged. The live imaging we show in Figure 2 illustrates that, just as happens in vivo, apical constriction is asynchronous. This means not all cells will have ‘bottle’ shapes in the same culture. We now illustrate the evolution of these shapes in more detail in [Supplementary Figure 1](#).

Additionally, the reviewer’s comment motivated us to investigate local buckles in the apical surface of our cultures when their apical surfaces are dilated by ROCK inhibition. We hypothesised that the very straight apical surface in normal cultures is achieved by a balance of apical cell size and tension with pressure differences at the cell-liquid interface. Consistent with our expectation, the apical surface of ROCK-inhibited cultures becomes wrinkled ([Supplementary figure 4](#)). The VANGL2-KI lines do not develop this tortuous apical surface (as shown in Figure 3), which is to be expected given their modification is present throughout differentiation unlike the acute dilation caused by ROCK inhibition.

This new data complements our visualisation of apical constriction in live imaging, apical accumulation of phospho-myosin, and quantification of ROCK-dependent apical tension as independent lines of evidence that our cultures undergo apical constriction.

(2) Another slight experimental concern I have regards the difference in laser ablation experiments detailed in Figure 3h-i from those of Figure 2d-e. It seems like WT recoil values in 3h-I are more variable and of a lower average than the earlier experiments and given that it appears significance is reached mainly by impact of the lower values, can the authors explain if this variability is expected to be due to heterogeneity in the tissue, i.e. some areas have higher local tension? If so, would that correspond with more local apical constriction?

There is no significant difference in recoil between the control lines in Figures 2 and 3, albeit the data in Figure 3 is more variable (necessitating more replicates: none were excluded). We also showed laser ablation recoil data in [Supplementary Figure 10](#), in which we did identify a graphing error (now corrected, also no significant difference in recoil from the other control groups as shown in Author response image 3).



Author response image 3. Recoil following laser ablation is not significantly different between different experiments. X axis labels indicate the figure panel each set of ablation data is shown in. Points represent an independent differentiation dish.

(4)(Minor) I think some of the commentary on the strengths and limitations of the model found in the Results section should be collated and moved to the discussion in a single paragraph. For example, this could also briefly touch on/compare to some of the other models utilizing hiPSCs (These are mentioned briefly in the intro, but this comparison could be elaborated on a bit after seeing all the great data in this work).

These changes have now been made:

Discussion: “Some of these limitations, potentially including inclusion of environmental risk factors, can be addressed by using alternative iPSC-derived models[93,94]. For example, if patients have suspected causative mutations in genes specific to the surface (non-neural) ectoderm, such as GRHL2/3, 3D models described by Karzbrun et al[49] or Huang et al[95] may be informative. Characterisation of surface ectoderm behaviours in those models is currently lacking. These models are particularly useful for high-throughput screens of induced mutations[95], but their reproducibility between cell lines, necessary to compare patient samples to non-congenic controls, remains to be validated. Spinal cell identities can be generated in human spinal cord organoids, although these have highly variable morphologies[96,97]. As such, each iPSC model presents limitations and opportunities, to

which this study contributes a reductionist and highly reproducible system in which to quantitatively compare multiple neuroepithelial functions.”

(5) While the authors are generally good about labeling figures by the day post smad inhibition, in some figures it is not clear either from the images or the legend text. I believe this includes supplemental figures 2,5,6,8, and 10 (apologies if I simply missed it in one or more of them)

These have now been added.

(6) The legend for Figure 2 refers to a panel that is not present and the remaining panel descriptions are off by a letter. I'm guessing this is a versioning error as the text itself seems largely correct, but it may be good to check for any other similar errors that snuck in

This has now been corrected.

(7) The cell outlines in Figure 3d are a bit hard to see both in print and on the screen, perhaps increase the displayed intensity?

This has now been corrected.


Description of analyses that authors prefer not to carry out

R2.5. Figure 3. The authors mention their previous study in which they show that Vangl2 is not cell-autonomously required for neural closure. It will be interesting to study whether this also the case in the present human model by using mosaic cultures.

The reviewer is correct that this is one of the exciting potential future applications of our model, which will first require us to generate stable fluorescently-tagged lines (to identify those cells which lack *VANGL2*). We will also need to extensively analyze controls to validate that mixing fluo-tagged and untagged lines does not alter the homogeneity of differentiation, or apical constriction, independently of *VANGL2* deletion. As such, the reviewer is suggesting an altogether new project which carries considerable risk and will require us to secure dedicated funding to undertake.

R3.8(Minor) The authors show a fascinating piece of data in [Supplementary Figure 1](#), demonstrating that nuclear volume is halved by day 8. Do they have any indication if the DNA content remains constant (e.g., integrated DAPI density)? I suppose it must, and this is a minor point in the grand scheme, but this represents a significant nuclear remodeling and may impact the overall DNA accessibility.

We agree with the reviewer that the reduction in nuclear volume is important data both because it informs understanding of the reduction in total cell volume, and because it suggests active chromatin compaction during differentiation. Unfortunately, the thicker epithelium and superimposition of nuclei in the differentiated condition means the laser light path is substantially different, making direct comparisons of intensity uninterpretable. Additionally, the apical-most nuclei will mostly be in G2/M phase due to interkinetic nuclear migration. As such, the comparison of DAPI integrated density between epithelial morphologies would not be informative (Author response image 4).



Author response image 4. Lateral views of DAPI-stained nuclei on Days 2 and 8 of differentiation. Note the rapid loss of staining intensity below the apical pseudo-row of nuclei on Day 8. This intensity change is likely due to the apical nuclei being in G2/M phase and therefore having more DNA, and rapid loss of 405nm wavelength signal at depth.

<https://doi.org/10.7554/eLife.110388.1.sa0>